WO2021007269A1

WO2021007269A1 - Bicyclic heterocycles as fgfr inhibitors

Info

Publication number: WO2021007269A1
Application number: PCT/US2020/041104
Authority: WO
Inventors: Oleg VECHORKIN; Chao QI; Minh Nguyen; Anlai Wang; Wenqing Yao
Original assignee: Incyte Corporation
Priority date: 2019-07-09
Filing date: 2020-07-08
Publication date: 2021-01-14
Also published as: US11591329B2; US20210009582A1

Abstract

The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer, Formula (I).

Description

BICYCLIC HETEROCYCLES AS FGFR INHIBITORS

FIELD OF THE INVENTION

The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the enzyme FGFR3 and are useful in the treatment of FGFR3-associated diseases such as cancer.

BACKGROUND OF INVENTION

The Fibroblast Growth Factor Receptors (FGFR) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFR1-4) that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation. Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005).

Aberrant activation of this pathway either through overexpression of FGF ligands or FGFR or activating mutations in the FGFRs can lead to tumor development, progression, and resistance to conventional cancer therapies. In human cancer, genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand- independent receptor activation have been described. Large scale DNA sequencing of thousands of tumor samples has revealed that components of the FGFR pathway are among the most frequently mutated in human cancer. Many of these activating mutations are identical to germline mutations that lead to skeletal dysplasia syndromes. Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities (Reviewed in Knights and Cook Pharmacology & Therapeutics, 2010; Turner and Grose, Nature Reviews Cancer, 2010). Therefore, development of inhibitors targeting FGFR may be useful in the clinical treatment of diseases that have elevated FGF or FGFR activity.

The cancer types in which FGF/FGFRs are implicated include, but are not limited to: carcinomas (e.g., bladder, breast, cervical, colorectal, endometrial, gastric, head and neck, kidney, liver, lung, ovarian, prostate); hematopoietic malignancies (e.g., multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, acute myelogenous leukemia, non- Hodgkin lymphoma, myeloproliferative neoplasms, and Waldenstrom's Macroglubulinemia); and other neoplasms (e.g., glioblastoma, melanoma, and rhabdosarcoma). In addition to a role in oncogenic neoplasms, FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.

There is a continuing need for the development of new drugs for the treatment of cancer, and the FGFR3 inhibitors described herein help address this need.

SUMMARY OF INVENTION

The present disclosure is directed to compounds having Formula (I):

or pharmaceutically acceptable salts thereof, wherein constituent variables are defined herein.

The present disclosure is further directed to pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

The present disclosure is further directed to methods of inhibiting an FGFR3 enzyme comprising contacting the enzyme with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The present disclosure is further directed to a method of treating a disease associated with abnormal activity or expression of an FGFR3 enzyme, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

The present disclosure is further directed to compounds of Formula (I) for use in treating a disease associated with abnormal activity or expression of an FGFR3 enzyme.

The present disclosure is further directed to a method for treating a disorder mediated by an FGFR3 enzyme, or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound of Formula (I), or pharmaceutically acceptable composition thereof.

The present disclosure is further directed to a method for treating a disorder mediated by an FGFR3 enzyme, or a mutant thereof, in a patient in need thereof, comprising the step of administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with another therapy or therapeutic agent as described herein.

The present disclosure is further directed to the use of compounds of Formula (I) in the preparation of a medicament for use in therapy.

DETAILED DESCRIPTION

Compounds

In one aspect, the present disclosure provides compounds of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

Cy¹ is selected from C_6-10 aryl and 5-10 membered heteroaryl; wherein each 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 5-10 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^A is selected from C3-12 cycloalkyl and 4-12 membered heterocycloalkyl; wherein each 4-12 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 4-12 membered

heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; wherein when the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl of Cy^A has a fused aromatic ring attached thereto, the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl is directly attached to the pyrazolopyridine core structure through a ring-forming atom of the saturated or partially saturated ring; and wherein the C3-12 cycloalkyl and 4-12 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰; R¹ is selected from H, D, halo, CN, C_1-6 alkyl, OR^a and NR^cR^d; wherein the C_1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^g;

R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C3-1₀ cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, CN, OR^a7, SR^a7, C(0)R^b7,

C(0)NR^c7R^d7, C(0)OR^a7, NR^c7R^d7, NR^c7C(0)R^b7, NR^c7C(0)0R^a7, NR^c7S(0)R^b7,

NR^c7S(0)₂R^b7, NR^c7S(0)₂NR^c7R^d7, S(0)R^b7, S(0)NR^c7R^d7, S(0)₂R^b7, and S(0)₂NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰;

each R¹⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, NO2, OR^al, SR^al, C(0)R^bl, C(0)NR^clR^dl, C(0)OR^al, OC(0)R^bl, OC(0)NR^clR^dl, NR^clR^dl, NR^clC(0)R^bl, NR^clC(0)OR^al, NR^clC(0)NR^clR^dl, C(=NR^el)R^bl, C(=NOR^al)R^bl, C(=NR^el)NR^clR^dl, NR^clC(=NR^el)NR^clR^dl, NR^clS(0)R^bl, NR^clS(0)₂R^bl, NR^clS(0)₂NR^clR^dl, S(0)R^bl,

S(0)NR^clR^dl, S(0)₂R^bl, and S(0)₂NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 1₀ aryl-C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, OR^a3, SR^a3, C(0)R^b3, C(0)NR^c3R^d3, C(0)OR^a3, NR^c3R^d3, NR^c3C(0)R^b3, NR^c3C(0)0R^a3, NR^c3S(0)R^b3, NR^c3S(0)₂R^b3, NR^c3S(0)₂NR^c3R^d3, S(0)R^b3, S(0)NR^c3R^d3, S(0)₂R^b3, and S(0)₂NR^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R¹² is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, 4-7 membered

heterocycloalkyl, halo, D, CN, OR^a5, SR^a5, C(0)R^b5, C(0)NR^c5R^d5, C(0)OR^a5, NR^c5R^d5, NR^c5C(0)R^b5, NR^c5C(0)0R^a5, NR^c5S(0)R^b5, NR^c5S(0)₂R^b5, NR^c5S(0)₂NR^c5R^d5, S(0)R^b5, S(0)NR^c5R^d5, S(0)₂R^b5, and S(0)₂NR^c5R^d5; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl and 4-7 membered

heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, NO2, OR^a2, SR³², C(0)R^b2, C(0)NR^c2R^d2, C(0)OR^a2, OC(0)R^b2, 0C(0)NR^c2R^d2, NR^c2R^d2, NR^c2C(0)R^b2, NR^c2C(0)0R^a2, NR^c2C(0)NR^c2R^d2, C(=NR^e2)R^b2, C(=NOR^a2)R^b2, C(=NR^e2)NR^c2R^d2, NR^c2C(=NR^e2)NR^c2R^d2, NR^c2S(0)R^b2, NR^c2S(0)₂R^b2, NR^c2S(0)₂NR^c2R^d2, S(0)R^b2,

S(0)NR^c2R^d2, S(0)₂R^b2, and S(0)₂NR^c2R^d2; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring, or a fused phenyl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6- membered heteroaryl ring, and fused phenyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹;

each R²¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, OR^a4, SR^a4, C(0)R^b4, C(0)NR^c4R^d4, C(0)0R^a4, NR^c4R^d4, NR^c4C(0)R^M, NR^c4C(0)0R^a4, NR^c4S(0)R^M, NR^c4S(0)₂R^M, NR^c4S(0)₂NR^c4R^d4, S(0)R^b4, S(0)NR^c4R^d4, S(0)₂R^M, and S(0)₂NR^c4R^d4; wherein said C_1-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

or two R²¹ substituents taken together with the carbon atom to which they are attached form a spiro 3-7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl ring has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each spiro 3-7-membered heterocycloalkyl ring is optionally substituted by oxo to form a carbonyl group; and wherein the spiro 3-7membered

heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2,

3 or 4 substituents independently selected from R²²;

each R²² is independently selected from C_1-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^a6, SR^a6, C(0)R^b6, C(0)NR^c6R^d6, C(0)OR^a6, NR^c6R^d6, NR^c6C(0)R^b6, NR^c6C(0)0R^a6, NR^c6S(0)R^b6, NR^c6S(0)₂R^b6, NR^c6S(0)₂NR^c6R^d6, S(0)R^b6, S(0)NR^c6R^d6, S(0)₂R^b6, and S(0)₂NR^c6R^d6; wherein said C_1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R³⁰ is independently selected from C_1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^a8, SR^a8, C(0)R^b8, C(0)NR^c8R^d8, C(0)OR^a8, NR^c8R^d8, NR^c8C(0)R^b8, NR^c8C(0)0R^a8, NR^c8S(0)R^b8, NR^c8S(0)₂R^b8, NR^c8S(0)₂NR^c8R^d8, S(0)R^b8, S(0)NR^c8R^d8, S(0)₂R^b8, and S(0)₂NR^c8R^d8; wherein said C_1-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^a, R^c and R^d is independently selected from H, C_1-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl and C 1-6 haloalkyl; wherein said C_1-6 alkyl, C₂-6 alkenyl and C₂-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^al, R^cl and R^dl is independently selected from H, C_1-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl, C 1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

or any R^cl and R^dl attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^bl is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R^el is independently selected from H, CN, C_1-6 alkyl, C_1-6 haloalkyl, C_1-6 alkylthio, C_1-6 alkylsulfonyl, C_1-6 alkylcarbonyl, C_1-6 alkylaminosulfonyl, carbamyl, C_1-6 alkylcarbamyl, di(C_1-6 alkyl)carbamyl, aminosulfonyl, C_1-6 alkylaminosulfonyl and di(C_1-6 alkyl)aminosulfonyl;

each R³², R^c2 and R^d2, is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C 1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or any R^c2 and R^d2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²¹;

each R^b2 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R^e2 is independently selected from H, CN, C_1-6 alkyl, C_1-6 haloalkyl, C_1-6 alkylthio, C_1-6 alkylsulfonyl, C_1-6 alkylcarbonyl, C_1-6 alkylaminosulfonyl, carbamyl, C_1-6 alkylcarbamyl, di(C_1-6 alkyl)carbamyl, aminosulfonyl, C_1-6 alkylaminosulfonyl and di(C_1-6 alkylaminosulfonyl;

each R^a3, R^c3 and R^d3, is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

or any R^c3 and R^d3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R¹²;

each R^b3 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered

heterocycloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R^a4, R^c4 and R^d4, is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

or any R^c4 and R^d4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R²²;

each R^b4 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered

heterocycloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R^a5, R^c5 and R^d5, is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl and C 1-6 haloalkyl; wherein said C_1-6 alkyl, C_2-6 alkenyl and C_2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

or any R^c5 and R^d5 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^b5 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl and C_1-6 haloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl and C_2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; each R^a6, R^c6 and R^d6, is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl and C_1-6 haloalkyl; wherein said C_1-6 alkyl, C_2-6 alkenyl and C_2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^b6 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, and C_1-6 haloalkyl; wherein said C_1-6 alkyl, C_2-6 alkenyl and C_2-6 alkynyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R^a7, R^c7, and R^d7 is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C 1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰;

or any R^c7 and R^d7 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R³⁰;

each R^b7 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl and 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰;

each R^a8, R^c8 and R^d8, is independently selected from H, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C 1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

or any R^c8 and R^d8 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R^g;

each R^b8 is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered

heterocycloalkyl; wherein said C_1-6 alkyl C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5- 6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g; and

each R^g is independently selected from OH, NO2, CN, halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C₃-₆ cycloalkyl, C₃-₆ cycloalkyl-Ci-2 alkylene, Ci-6 alkoxy, C_1-6 haloalkoxy, C1-3 alkoxy-C_1-3 alkyl, C1-3 alkoxy-C_1-3 alkoxy, HO-C1-3 alkoxy, HO-C1-3 alkyl, cyano-C 1-3 alkyl, H2N-C1-3 alkyl, amino, C_1-6 alkylamino, di(C_1-6 alkyl)amino, thio, C_1-6 alkylthio, C_1-6 alkylsulfmyl, C_1-6 alkylsulfonyl, carbamyl, C_1-6 alkylcarbamyl, di(C_1-6 alkyl)carbamyl, carboxy, C_1-6 alkyl carbonyl, C_1-6 alkoxycarbonyl, C_1-6 alkylcarbonylamino, C_1-6 alkylsulfonylamino, aminosulfonyl, C_1-6 alkylaminosulfonyl, di(C_1-6 alkyl)aminosulfonyl, aminosulfonylamino, C_1-6 alkylaminosulfonylamino, di(C_1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C_1-6 alkylaminocarbonylamino, and di(C_1-6 alkyl)aminocarbonylamino.

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹ is selected from:

(i) C6-10 aryl,

(ii) monocyclic 5-6 membered heteroaryl, wherein each monocyclic 5-6 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; and

(iii) bicyclic 8-10 membered heteroaryl, wherein each bicyclic 8-10 membered heteroaryl has at least one ring -forming carbon atom, and 1, 2, or 3 ring-forming heteroatoms independently selected from O and S, and optionally 1, 2 or 3 ring-forming heteroatoms that are N;

wherein the N and S of the monocyclic 5-6 membered heteroaryl and bicyclic 8-10 membered heteroaryl of Cy¹ are optionally oxidized; a ring-forming carbon atom of monocyclic 5-6 membered heteroaryl and bicyclic 8-10 membered heteroaryl of Cy¹ is optionally substituted by oxo to form a carbonyl group; and the C6-10 aryl, monocyclic 5-6 membered heteroaryl, and bicyclic 8-10 membered heteroaryl of Cy¹ are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

each R¹⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, NO2, OR^al, SR^al, C(0)R^bl, C(0)NR^clR^dl, C(0)OR^al, OC(0)R^bl, OC(0)NR^clR^dl, NR^clR^dl, NR^clC(0)R^bl, NR^clC(0)OR^al, NR^clC(0)NR^clR^dl, C(=NR^el)R^bl, C(=NOR^al)R^bl, C(=NR^el)NR^clR^dl, NR^clC(=NR^el)NR^clR^dl, NR^clS(0)R^bl, NR^clS(0)₂R^bl, NR^clS(0)₂NR^clR^dl, S(0)R^bl,

S(0)NR^clR^dl, S(0)₂R^bl, and S(0)₂NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 1₀ aryl -C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, OR^a3, SR^a3, C(0)R^b3, C(0)NR^c3R^d3, C(0)OR^a3, NR^c3R^d3, NR^c3C(0)R^b3, NR^c3C(0)0R^a3, NR^c3S(0)R^b3, NR^c3S(0)₂R^b3, NR^c3S(0)₂NR^c3R^d3, S(0)R^b3, S(0)NR^c3R^d3, S(0)₂R^b3, and S(0)₂NR^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

3 or 4 substituents independently selected from R²²;

In some embodiments, Cy¹ is selected from monocyclic C6-10 aryl and monocyclic 5-6 membered heteroaryl; wherein each monocyclic 5-6 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the monocyclic 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the monocyclic C6-10 aryl and monocyclic 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹ is selected from phenyl and monocyclic 5-6 membered heteroaryl having at least one ring-forming carbon atom and 1, 2, 3 or 4 ring-forming nitrogen atoms; wherein the phenyl and monocyclic 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹ is a monocyclic 5-6 membered heteroaryl having at least one ring -forming carbon atom and 1, 2, 3 or 4 ring-forming nitrogen atoms, optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹ is selected from thienopyridinyl, pyrazolyl, triazolyl and phenyl; wherein thienopyridinyl, pyrazolyl, triazolyl and phenyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰. In some

embodiments, Cy¹ is pyrazolyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰. In some embodiments, Cy¹ is triazolyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰. In some

embodiments, Cy¹ is phenyl optionally substituted with 1, 2, 3 or 4 substituents

independently selected from R¹⁰. In some embodiments, Cy¹ is thienopyridinyl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

In some embodiments, Cy¹ is selected from 1 -methyl- lH-pyrazol-4-yl, 1 -methyl- 1H- l,2,3-triazol-4-yl, l-(pyridin-3-ylmethyl)-lH-pyrazol-4-yl, l-(2-morpholinoethyl)-lH- pyrazol-4-yl, 3-fluoro-4-(4-methylpiperazin-l-yl)phenyl, and thieno[3,2-c]pyri din-2 -yl. In some embodiments, each R¹⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered

heterocycloalkyl-C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl -C 1-3 alkylene, halo, D, CN, NO2, OR^al, SR^al, C(0)R^bl, C(0)NR^clR^dl, C(0)OR^al, OC(0)R^bl, OC(0)NR^clR^dl, and NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R¹⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, halo, D, CN, OR^al,

C(0)NR^clR^dl and NR^clR^dl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R¹⁰ is independently selected from C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and halo; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

In some embodiments, each R¹⁰ is independently selected from C_1-6 alkyl, 4-10 membered heterocycloalkyl, and halo; wherein said C_1-6 alkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹. In some embodiments, R¹⁰ is C_1-6 alkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹. In some embodiments, R¹⁰ is 4-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents

independently selected from R¹¹. In some embodiments, R¹⁰ is halo. In some embodiments, R¹⁰ is fluoro, chloro, or bromo. In some embodiments, wherein R¹⁰ is fluoro.

In some embodiments, each R¹⁰ is independently selected from methyl, 4- methylpiperazin-l-yl, 2-morpholinoethyl, pyridin-3-ylmethyl and fluoro. In some embodiments, wherein each R¹⁰ is methyl.

In some embodiments, each R¹¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl -C_1-3 alkylene, halo, D, CN, OR^a3, SR^a3, C(0)R^b3, C(0)NR^c3R^d3, C(0)0R^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl -C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹².

In some embodiments, each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a3, SR^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹².

In some embodiments, each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, halo, D, CN, OR^a3 and NR^c3R^d3; wherein said C_1-6 alkyl, 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹².

In some embodiments, each R¹¹ is independently selected from 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl. In some embodiments, R¹¹ is 4-10 membered heterocycloalkyl. In some embodiments, R¹¹ is 5-6 membered heterocycloalkyl.

In some embodiments, R¹¹ is 5-10 membered heteroaryl. In some embodiments, wherein R¹¹ is 5-6 membered heteroaryl. In some embodiments, each R¹¹ is independently selected from 2-morpholino and pyridin-3-yl.

In some embodiments, Cy^A is 4-12 membered heterocycloalkyl; wherein the 4-12 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 4-12 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 4-12 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^A is 5-8 membered heterocycloalkyl; wherein the 5-8 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2 or 3 ring forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of 5-8 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 5-8 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^A is 6 membered heterocycloalkyl; wherein the 6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1 or 2 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of 6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 6 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^A is 6-membered heterocycloalkyl selected from

piperazinyl, piperidinyl, 5,6-dihydroimidazo[l,5-a]pyrazin-7(8H)-yl and 6,7- dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl; wherein a ring-forming carbon atom of the 6- membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 6 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^A is piperazinyl; wherein a ring-forming carbon atom of piperazinyl is optionally substituted by oxo to form a carbonyl group; and the piperazinyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^A is piperidinyl; wherein a ring-forming carbon atom of piperidinyl is optionally substituted by oxo to form a carbonyl group; and the piperidinyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

In some embodiments, Cy^A is 4-methyl-3-oxopiperazin-l-yl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰.

In some embodiments, Cy^A is 4-12 membered heterocycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰; wherein the 4-12 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from N, O, and S; wherein at least one of the ring forming heteroatoms is N and wherein the 4-12 membered heterocycloalkyl is attached to the pyrazolopyridine core structure through a ring forming nitrogen atom.

In some embodiments, Cy^A is 4-12 membered heterocycloalkyl, wherein a ring forming carbon atom of the 4-12 membered heterocycloalkyl is substituted by oxo to form a carbonyl group.

In some embodiments, Cy^A is selected from 3-hydroxypiperidin-l-yl, 6,7- dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl, l-(trifluoromethyl)-5,6-dihydroimidazo[l,5- a]pyrazin-7(8H)-yl, 3-methyl-2-oxo-3,8-diazabicyclo[3.2. l]octan-8-yl, 2-isopropyl-4-methyl- 3-oxopiperazin-l-yl, 2-ethyl -4-methyl -3-oxopiperazin-l-yl, 2,2-diethyl-4-methyl-3- oxopiperazin-l-yl, 2-benzyl-4-methyl-3-oxopiperazin-l-yl, 2-(cyclopropylmethyl)-4-methyl- 3-oxopiperazin-l-yl, 4-methyl-3-oxo-2-(tetrahydro-2H-pyran-4-yl)piperazin-l-yl, 4-methyl- 3 -oxo-2-(pyridin-4-ylmethyl)piperazin- 1 -yl, 4-methyl-3-oxo-2-( 1 -phenylethyl)piperazin- 1 -yl, 2-cyclopropyl-4-methyl-3-oxopiperazin-l-yl, 4-cyclopropyl-2-methyl-3-oxopiperazin-l-yl, and 2,4,5 -trimethyl -3 -oxopiperazin- 1 -yl .

In some embodiments, each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, halo, D, CN, OR^a2,

C(0)NR^c2R^d2 and NR^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring, or a fused phenyl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6- membered heteroaryl ring, and fused phenyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹.

C(0)NR^c2R^d2 and NR^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and OR^a2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring, or a fused phenyl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6-membered heteroaryl ring, and fused phenyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹.

In some embodiments, each R²⁰ is independently selected from OH, methyl, ethyl, isopropyl, cyclopropyl, and tetrahydropyran, each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused pyrazole or imidazole; each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused bicycle such that Cy^A is selected from 5,6-dihydroimidazo[l,5-a]pyrazin-7(8H)-yl and 6,7-dihydropyrazolo[l,5-a]pyrimidin- 4(5H)-yl; wherein each fused bicycle is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

In some embodiments, each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a4 and NR^c4R^d4; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

In some embodiments, each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²². In some embodiments, each R²¹ is independently selected from C_1-6 haloalkyl, C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl; wherein said C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

In some embodiments, each R²¹ is independently selected from C_1-6 haloalkyl, C_3-10 cycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl. In some embodiments, each R²¹ is C_1-6 haloalkyl. In some embodiments, each R²¹ is C_3-10 cycloalkyl. In some embodiments, each R²¹ is C6-10 aryl. In some embodiments, each R²¹ is 5-10 membered heteroaryl. In some embodiments, each R²¹ is independently selected from trifluoromethyl, phenyl, pyridine and cyclopropyl.

In some embodiments, each R^a2, R^c2 and R^d2, is independently selected from H and C_1-6 alkyl. In some embodiments, each R^a2 is H. In some embodiments, R¹ is selected from H, D, and C_1-6 alkyl. In some embodiments, R¹ is H.

In some embodiments, R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl -C1-3 alkylene, C6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, CN, OR^a7, SR^a7, C(0)R^b7, C(0)NR^c7R^d7, C(0)OR^a7, NR^c7R^d7, NR^c7C(0)R^b7, NR^c7C(0)0R^a7, NR^c7S(0)R^b7, NR^c7S(0)₂R^b7, NR^c7S(0)₂NR^c7R^d7, S(0)R^b7, S(0)NR^c7R^d7, S(0)₂R^b7, and S(0)₂NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl-C 1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰.

In some embodiments, R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 1₀ aryl -C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, CN, OR^a7, and NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰.

In some embodiments, R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-3 alkylene, halo, CN, OR^a7, and NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C6-10 aryl, 5-10 membered heteroaryl, and C6-10 aryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰. In some embodiments, R² is selected from H,

D, C_1-6 alkyl, 5-10 membered heteroaryl, C6-10 aryl-C_1-3 alkylene, halo, CN and OR^a7; wherein said C_1-6 alkyl 5-10 membered heteroaryl, and C6-10 aryl-C_1-3 alkylene are each optionally substituted with 1, 2 or 3 substituents independently selected from R³⁰. In some

embodiments, R² is selected from H, methyl, methoxy, chloride, nitrile, furanyl, and benzyl. In some embodiments, R² is H.

In some embodiments, each R³⁰ is independently selected from C_1-6 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; wherein said C_1-6 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g. In some embodiments, each R³⁰ is independently selected from C_1-6 alkyl and phenyl. In some embodiments, each R³⁰ is phenyl.

In some embodiments, each R^a7 is independently selected from H and C_1-6 alkyl. In some embodiments, each R^a7 is methyl.

In some embodiments the compound of Formula I is a compound of Formula Ila:

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, 3, or 4.

In some embodiments the compound of Formula I is a compound of Formula lib:

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

In some embodiments the compound of Formula I is a compound of Formula lie:

or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2.

In some embodiments the compound of Formula I is a compound of Formula lid:

lid

or a pharmaceutically acceptable salt thereof, wherein v is 1, 2, 3 or 4.

In some embodiments the compound of Formula I is a compound of Formula III:

or a pharmaceutically acceptable salt thereof, wherein q is 1, 2, or 3.

In some embodiments the compound of Formula I is a compound of Formula IVa:

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, 3, or 4 and q is 1, 2, or 3.

In some embodiments the compound of Formula I is a compound of Formula IVb:

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3 and wherein q is 1, 2, or 3.

In some embodiments the compound of Formula I is a compound of Formula IVc:

or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2 and wherein q is 1, 2, or 3. In some embodiments the compound of Formula I is a compound of Formula IVd:

or a pharmaceutically acceptable salt thereof, wherein v is 1, 2, 3 or 4 and wherein q is 1, 2, or 3.

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹ is selected from monocyclic C6-10 aryl and monocyclic 5-6 membered heteroaryl; wherein each monocyclic 5-6 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of the monocyclic 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the monocyclic C6-10 aryl and monocyclic 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^A is selected from 4-12 membered heterocycloalkyl; wherein the 4-12 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 4-12 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 4-12 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹ is selected from H, D, halo, CN, C_1-6 alkyl, OR^a and NR^cR^d; wherein the C_1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R^g;

R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, CN, and OR^a7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl- C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰;

each R¹⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, NO2, OR^al, SR^al, C(0)R^bl, C(0)NR^clR^dl, C(0)OR^al, OC(0)R^bl, OC(0)NR^clR^dl, and NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered

heterocycloalkyl-C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, OR^a3, SR^a3, C(0)R^b3, C(0)NR^c3R^d3, C(0)OR^a3, and R^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

heterocycloalkyl, halo, D, CN, OR^a5, SR^a5, C(0)R^b5, C(0)NR^c5R^d5, C(0)OR^a5, NR^c5R^d5, and NR^c5C(0)R^b5; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, C6-10 aryl, 5- 10 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, halo, D, CN, OR^a2, C(0)NR^c2R^d2 and NR^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring, or a fused phenyl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6- membered heteroaryl ring, and fused phenyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹; and

each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a4 and NR^c4R^d4; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

3 or 4 substituents independently selected from R²².

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹ is selected from phenyl and monocyclic 5-6 membered heteroaryl having at least one ring -forming carbon atom and 1, 2, 3 or 4 ring-forming nitrogen atoms; wherein the phenyl and monocyclic 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^A is selected from 6 membered heterocycloalkyl; wherein the 6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1 or 2 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of 6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 6 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹ is selected from H, D, and C_1-6 alkyl;

R² is selected from H, D, C_1-6 alkyl, C_1-6 haloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-3 alkylene, halo, CN, and OR^a7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C6-10 aryl, 5-10 membered heteroaryl, and C6-10 aryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰; each R¹⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, halo, D, CN, OR^al, C(0)NR^clR^dl and NR^clR^dl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a3, SR^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered

heterocycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6-membered heteroaryl ring, is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹; and each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, C6- 10 aryl, and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

In some embodiments, provided herein is a compound of Formula (I), wherein:

Cy¹ is selected from pyrazolyl, triazolyl and phenyl; wherein the pyrazolyl, triazolyl and phenyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰; Cy^A is 4-12 membered heterocycloalkyl; wherein each 4-12 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 4-12 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 4-12 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹ is H;

R² is selected from H, D, C_1-6 alkyl, 5-10 membered heteroaryl, halo, CN and OR^a7; wherein said C_1-6 alkyl is optionally substituted with 1, 2 or 3 substituents independently selected from R³⁰;

each R¹⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, halo, D, CN, OR^al, C(0)NR^clR^dl and R^clR^dl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, halo, D, CN, OR^a3 and NR^c3R^d3; wherein said C_1-6 alkyl, 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, halo, D, CN, OR^a2, C(0)NR^c2R^d2 and NR^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a4 and NR^c4R^d4. _wh_erein

c _I -₆ alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R³⁰ is independently selected from C_1-6 alkyl and phenyl;

each R³², R^c2 and R^d2, is independently selected from H and C_1-6 alkyl; and each R^a7 is independently selected from H and C_1-6 alkyl.

In some embodiments, provided herein is a compound of Formula (I), wherein: Cy¹ is selected from pyrazolyl, triazolyl, phenyl and thienopyridinyl; wherein the pyrazolyl; triazolyl and phenyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^A is 4-12 membered heterocycloalkyl; wherein each 4-12 membered

heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring -forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 4-12 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 4-12 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰;

R¹ is H;

R² is selected from H, C_1-6 alkyl, 5-10 membered heteroaryl, halo, CN and OMe; wherein said C_1-6 alkyl is optionally substituted with 1, 2 or 3 substituents independently selected from R³⁰;

each R¹⁰ is independently selected from C_1-6 alkyl, and 4-10 membered

heterocycloalkyl, halo; wherein said C_1-6 alkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl; wherein said 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, and OH; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R²¹ is independently selected from C_3-10 cycloalkyl, C6-10 aryl, and 5-10 membered heteroaryl; and

each R³⁰ is phenyl.

In some embodiments, the compound of Formula I is selected from:

l-(3-(l-Methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)piperidin-3-ol;

3-(l-Methyl-lH-pyrazol-4-yl)-5-(l-(trifluoromethyl)-5,6-dihydroimidazo[l,5- a]pyrazin-7(8H)-yl)-lH-pyrazolo[4,3-b]pyridine;

5-(6,7-Dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl)-3-(l -methyl- lH-pyrazol-4-yl)- 1H- pyrazolo[4,3-b]pyridine; 3-Methyl-8-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-3, 8- diazabicyclo[3.2.1 ]octan-2-one;

3-Isopropyl-l-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5- yl)piperazin-2-one;

3-Ethyl- l-methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyridin-5- yl)piperazin-2-one;

3, 3-Diethyl- l-methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyridin-5- yl)piperazin-2-one;

3-Benzyl-l -methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyridin-5- yl)piperazin-2-one;

3-(Cyclopropylmethyl)-l-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3- b]pyridin-5-yl)piperazin-2-one;

l-Methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyri din-5-yl)-3- (tetrahydro-2H-pyran-4-yl)piperazin-2-one;

l-Methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyri din-5-yl)-3- (pyridin-4-ylmethyl)piperazin-2-one;

l-Methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyri din-5-yl)-3-(l- phenylethyl)piperazin-2-one;

3-Cyclopropyl-l-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin- 5 -yl)piperazin-2-one;

l-Cyclopropyl-3-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin- 5 -yl)piperazin-2-one;

1, 3, 6-Trimethyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyridin-5- yl)piperazin-2-one;

3 -Isopropyl- 1 -methyl -4-(3 -( 1 -(pyri din-3 -ylmethyl)- 1 H-pyrazol-4-yl)- 1 H- pyrazolo[4,3-b]pyridin-5-yl)piperazin-2-one;

3 -Isopropyl- 1 -methyl -4-(3 -( 1 -(2-morpholinoethyl)- 1 H-pyrazol-4-yl)- 1 H- pyrazolo[4,3-b]pyridin-5-yl)piperazin-2-one;

4-(3-(3-Fluoro-4-(4-methylpiperazin-l-yl)phenyl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-3- isopropyl- 1 -methylpiperazin-2-one;

3-Isopropyl-l-methyl-4-(3-(thieno[3,2-c]pyridin-2-yl)-lH-pyrazolo[4,3-b]pyridin-5- yl)piperazin-2-one;

3-Isopropyl-l -methyl -4-(3-(l -methyl-lH- 1,2, 3-triazol-4-yl)-lH-pyrazolo[4, 3- b]pyridin-5-yl)piperazin-2-one; 4-(6-Chloro-3 -( 1 -methyl- lH-pyrazol-4-yl)- lH-pyrazolo[4, 3 -b]pyridin-5-yl)- 1,3- dimethylpiperazin-2-one;

1, 3-Dimethyl -4-(6-methyl-3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyri din- 5 -yl)piperazin-2-one;

5-(2, 4-Dimethyl -3-oxopiperazin-l-yl)-3-(l -methyl- lH-pyrazol-4-yl)-lH- pyrazolo[4,3-b]pyridine-6-carbonitrile;

4-(6-Methoxy-3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyri din-5-yl)-l, 3- dimethylpiperazin-2-one;

4-(6-(Furan-3-yl)-3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-l,3- dimethylpiperazin-2-one; and

4-(6-Benzyl-3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)- 1,3- dimethylpiperazin-2-one;

or a pharmaceutically acceptable salt thereof.

It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term“C_1-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and Ce alkyl.

At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term“a pyridine ring” or“pyridinyl” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.

The term“n-membered” where n is an integer typically describes the number of ring forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group. For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R.

Definitions

As used herein, the phrase“optionally substituted” means unsubstituted or substituted.

As used herein, the term“substituted” means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency.

As used herein, the term“Ci-j,” where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, C_1-6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.

As used herein, the term“alkyl,” employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some embodiments, the alkyl group contains 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, .sec-butyl, /er/-butyl, «-pentyl, 2-methyl- 1 -butyl, 3- pentyl, «-hexyl, 1,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl.

As used herein, the term "Ci-j alkylene," employed alone or in combination with other terms, means a saturated divalent linking hydrocarbon group that may be straight-chain or branched, having i to j carbons. In some embodiments, the alkylene group contains from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or from 1 to 2 carbon atoms. Examples of alkylene moieties include, but are not limited to, chemical groups such as methylene, ethylene, 1,1- ethylene, 1,2-ethylene , 1,3 -propylene, 1,2-propylene, 1,1 -propylene, isopropylene, and the like.

As used herein,“alkenyl,” employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, «-propenyl, isopropenyl, «-butenyl, .v c-butenyl, and the like. As used herein,“alkynyl,” employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like.

As used herein,“halo” or“halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. In some embodiments, halo is F.

As used herein, the term“haloalkyl,” employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCh, CHCI2, C2CI5, and the like.

As used herein, the term“alkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-alkyl. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, alkoxy is methoxy.

As used herein,“haloalkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. An example haloalkoxy group is -OCF3.

As used herein,“amino,” employed alone or in combination with other terms, refers to NFb.

As used herein, the term“alkylamino,” employed alone or in combination with other terms, refers to a group of formula -NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms. Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.

As used herein, the term“dialkylamino,” employed alone or in combination with other terms, refers to a group of formula -N(alkyl)2. Example dialkylamino groups include dimethylamino, diethylamino, dipropylamino (e.g., di(n-propyl)amino and

di(isopropyl)amino), and the like. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms. As used herein, the term“alkylthio,” employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

As used herein, the term“cycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term“cycloalkyl” also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7 monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl,

octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

As used herein, the term“heterocycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of

heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-l-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring. In some embodiments, the heterocycloalkyl is a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the

heterocycloalkyl is 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.

As used herein, the term“aryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1 -naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl.

As used herein, the term“heteroaryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[l,2-b]thiazolyl or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In one embodiment the heteroaryl group is a 5 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 5 to 6 membered heteroaryl group. In some embodiments, the heteroaryl is a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S. In some embodiments, the heteroaryl is a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S.

The compounds described herein can be asymmetric ( e.g ., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.

Resolution of racemic mixtures of compounds can be carried out by methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g., S and A forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2- diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2, 4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.

The term,“compound,” as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted.

All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated.

In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By“substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

The phrase“pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences , 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science , 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

The following abbreviations may be used herein: AcOH (acetic acid); AC2O (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (/-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc (calculated); d (doublet); dd (doublet of doublets); DCM

(dichloromethane); DEAD (diethyl azodi carboxyl ate); DIAD (A, A -diisopropyl

azidodi carboxyl ate); DIPEA (A,A-diisopropylethylamine); DMF (A,A-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (A,A,A',A'-tetramethyl-O- (7-azabenzotriazol-l-yl)uronium hexafluorophosphate); HC1 (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography - mass spectrometry); m (multiplet); M (molar); wCPBA (3- chloroperoxybenzoic acid); MgSCri (magnesium sulfate); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); NaHCCh (sodium bicarbonate); NaOH (sodium hydroxide); Na₂SO ₄ (sodium sulfate); MLCl (ammonium chloride); NH4OH

(ammonium hydroxide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM (picomolar); PMB (para- methoxybenzyl), POCh (phosphoryl chloride); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); /-Bu (/er/-butyl); TFA (trifluoroacetic acid); THF

(tetrahydrofuran); pg (microgram(s)); mL (microliter(s)); pM (micromolar); wt% (weight percent). Synthesis

Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and according to various possible synthetic routes.

The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

Preparation of compounds of the invention can involve the protection and

deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis , 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.

Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ¾ or ¹³C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

The expressions,“ambient temperature,”“room temperature,” and“r.t”, as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.

Compounds described herein can be prepared by one skilled in the art according to preparatory routes known in the literature. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below. Scheme 1.

Compounds of formula 1-4 can be prepared via the synthetic route outlined in Scheme

1

A halogenation reaction of 1-1 can be carried out using an appropriate reagent, such as N- iodosuccinimide, followed by NH protection to afford compounds of formula 1-2. The compounds of formula 1-2 can be cross-coupled with Cy^x-M, in which M is a boronic acid, boronic ester or an appropriately substituted metal [e.g, M is B(OR)2, Sn(Alkyl)3, or Zn- Hal], under standard Suzuki Cross-Coupling conditions (e.g, in the presence of a palladium catalyst and a suitable base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst) (ACS Catalysis 2015, 5, 3040-3053), or standard Negishi cross coupling conditions (e.g, in the presence of a palladium catalyst) (ACS Catalysis 2016, 6, 1540-1552) to generate compounds of formula 1-3. Buchwald-Hartwig reaction of 1-3 with an appropriate amine can then be carried out using standard Buchwald-Hartwig cross coupling conditions (e.g, in the presence of a palladium catalyst and a suitable base) (Chem. Sci. 2011, 2, 27-50), followed by deprotection of the protective group to afford compounds of formula 1-4.

Scheme 2.

Compounds of formula 2-2 and 2-3 can be prepared via the synthetic route outlined in Scheme 2. A Buchwald-Hartwig reaction of 1-3 (prepared using procedures from Scheme 1) with an appropriate amine can be carried out using standard Buchwald-Hartwig cross coupling conditions ( e.g ., in the presence of a palladium catalyst and a suitable base) to afford compounds of formula 2-1. Alkylation of 2-1 can be conducted using appropriate base (e.g. LDA) and R²⁰-Hal (Hal is a halide, such as Cl, Br, or I) to afford mono and double alkylated products 2-2 and 2-3.

Scheme 3.

Compounds of formula 1-4 can be alternatively prepared via the synthetic route outlined in Scheme 3. Protection of 1-1 results in the formation of compounds of formula 3-1. Reaction of 3-1 with an appropriate amine under standard Buchwald-Hartwig cross-coupling conditions ( e.g ., in the presence of a palladium catalyst and a suitable base) followed by deprotection can afford compounds of formula 3-2. A halogenation reaction of 3-2 can be carried out using an appropriate reagent, such as N-iodosuccinimide, followed by NH protection results in compounds of formula 3-3. The compounds 3-3 can then be cross- coupled with Cy^x-M, where M is a boronic acid, boronic ester or an appropriately substituted metal [e.g., M is B(OR)2, Sn(Alkyl)3, or Zn-Hal], under standard Suzuki cross-coupling conditions (e.g, in the presence of a palladium catalyst and a suitable base) (Tetrahedron 2002, 58, 9633-9695), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g, in the presence of a palladium catalyst) to generate intermediate 3-4, which can then be deprotected to afford compounds of formula 1-4. Scheme 4.

Compounds of formula 4-8 can be prepared via the synthetic route outlined in Scheme 4. A halogenation reaction of 4-1 can be carried out using an appropriate reagent, such as N- bromosuccinimide, followed by protection with acetic anhydride to afford compounds of formula 4-2. A reaction of 4-2 with isopentyl nitrite results in the formation of 4-3, which can then be deprotected to afford 4-4. Halogenation and protection of 4-4 using N- iodosuccinimide and an appropriate protective group can deliver compound 4-5. A cross coupling reaction can be performed between 4-5 and Cy^x-M in which M is a boronic acid, boronic ester or an appropriately substituted metal [ e.g ., M is B(OR)2, Sn(Alkyl)3, or Zn- Hal], under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g, in the presence of a palladium catalyst) to generate compounds of formula 4-6, which can be used in

Buchwald-Hartwig cross-coupling reaction to provide compounds of formula 4-7. Finally, another cross-coupling reaction between 4-7 and an appropriate coupling partner can be performed using similar conditions as described for the transformation from 4-5 to 4-6 or transformation from 4-6 to 4-7 to afford compounds of formula 4-8.

Methods of Use

Compounds of the present disclosure can inhibit the activity of the FGFR enzyme. For example, compounds of the present disclosure can be used to inhibit activity of an FGFR enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient. Compounds of the present disclosure can be used to inhibit activity of the FGFR3 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of one or more compounds of the present disclosure to the cell, individual, or patient.

As FGFR inhibitors, the compounds of the present disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR enzyme or FGFR ligands. Compounds which inhibit FGFR will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that compounds of the present disclosure will prove useful in treating or preventing proliferative disorders such as cancers. In particular, tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.

In certain embodiments, the disclosure provides a method for treating a FGFR- mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound according to the invention, or a pharmaceutically acceptable composition thereof.

In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.

Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET), 8pl l myeloproliferative syndrome),

myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, adult T-cell leukemia, Waldenstrom's

Macroglubulinemia, hairy cell lymphoma, marginal zone lymphoma, chronic myelogenic lymphoma and Burkitf s lymphoma.

Exemplary sarcomas include chondrosarcoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, lymphosarcoma, leiomyosarcoma, and teratoma.

Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, mesothelioma, pavicellular and non-pavicellular carcinoma, bronchial adenoma and pleuropulmonary blastoma.

Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (exocrine pancreatic carcinoma, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel

(adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, gall bladder cancer and anal cancer.

Exemplary genitourinary tract cancers include cancers of the kidney

(adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate

(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma,

teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma,

fibroadenoma, adenomatoid tumors, lipoma) and urothelial carcinoma.

Exemplary liver cancers include hepatoma (hepatocellular carcinoma),

cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma,

chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors

Exemplary nervous system cancers include cancers of the skull (osteoma,

hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors, neuro-ectodermal tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), neuroblastoma, Lhermitte-Duclos disease and pineal tumors.

Exemplary gynecological cancers include cancers of the breast (ductal carcinoma, lobular carcinoma, breast sarcoma, triple-negative breast cancer, HER2-positive breast cancer, inflammatory breast cancer, papillary carcinoma), uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).

Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.

Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and

parathyroid cancers, tumors of the eye, tumors of the lips and mouth and squamous head and neck cancer.

The compounds of the present disclosure can also be useful in the inhibition of tumor metastases.

In addition to oncogenic neoplasms, the compounds of the invention are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare- Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes. In some embodiments, the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder.

In some embodiments, compounds described herein can be used to treat Alzheimer’s disease, HIV, or tuberculosis.

As used herein, the term“8pl 1 myeloproliferative syndrome” is meant to refer to myeloid/lymphoid neoplasms associated with eosinophilia and abnormalities of FGFR1.

As used herein, the term“cell” is meant to refer to a cell that is in vitro , ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal. As used herein, the term“contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example,“contacting” the FGFR enzyme with a compound described herein includes the administration of a compound described herein to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound described herein into a sample containing a cellular or purified preparation containing the FGFR enzyme.

As used herein, the term“individual” or“patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

As used herein, the phrase“therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent such as an amount of any of the solid forms or salts thereof as disclosed herein that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. An appropriate "effective" amount in any individual case may be determined using techniques known to a person skilled in the art.

The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, the phrase "pharmaceutically acceptable carrier or excipient" refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, non-toxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. In one embodiment, each component is "pharmaceutically acceptable" as defined herein. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et ak, Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009.

As used herein, the term "treating" or "treatment" refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.„ reversing the pathology and/or symptomatology) such as decreasing the severity of disease.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

Combination Therapy

One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy ( e.g .,

IL2, GM-CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with compounds described herein for treatment of FGFR-associated diseases, disorders or conditions, or diseases or conditions as described herein. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered

simultaneously or sequentially as separate dosage forms.

Compounds described herein can be used in combination with one or more other kinase inhibitors for the treatment of diseases, such as cancer, that are impacted by multiple signaling pathways. For example, a combination can include one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGF-PR, Pirn, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFpR, CSFIR, KIT, FLK-II, KDR/FLK- 1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Additionally, the solid forms of the FGFR inhibitor as described herein can be combined with inhibitors of kinases associated with the PIK3/Akt/mTOR signaling pathway, such as PI3K, Akt (including Aktl, Akt2 and Akt3) and mTOR kinases. In some embodiments, compounds described herein can be used in combination with one or more inhibitors of the enzyme or protein receptors such as HPK1, SBLB, TUT4, A2A/A2B, CD47, CDK2, STING, ALK2, LIN28, AD AR1, MAT2a, RIOK1, HDAC8, WDR5, SMARCA2, and DCLK1 for the treatment of diseases and disorders. Exemplary diseases and disorders include cancer, infection, inflammation and neurodegenerative disorders.

In some embodiments, compouds described herein can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. Histone deacetylase inhibitors include, e.g, vorinostat.

For treating cancer and other proliferative diseases, compounds described herein can be used in combination with targeted therapies, including JAK kinase inhibitors (Ruxolitinib, additional JAK1/2 and JAK 1- selective, baricitinib or INCB39110), Pirn kinase inhibitors (e.g., LGH447, INCB053914 and SGI-1776), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors (e.g., INCB50465 and INCB54707), PI3K- gamma inhibitors such as PI3K-gamma selective inhibitors, MEK inhibitors, CSF1R inhibitors (e.g., PLX3397 and LY3022855), TAM receptor tyrosine kinases inhibitors (Tyro- 3, Axl, and Mer; e.g., INCB81776), angiogenesis inhibitors, interleukin receptor inhibitors, Cyclin Dependent kinase inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (Bortezomib, Carfilzomib), HD AC -inhibitors (panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors, such as OTX015, CPI- 0610, INCB54329 or INCB57643), LSD1 inhibitors (e.g., GSK2979552, INCB59872 and INCB60003), arginase inhibitors (e.g., INCB1158), indoleamine 2,3 -di oxygenase inhibitors (e.g., epacadostat, NLG919 or BMS-986205), PARP inhibiors (e.g., olaparib or rucaparib), inhibitors of BTK such as ibrutinib, c-MET inhibitors (e.g, capmatinib), an ALK2 inhibitor (e.g, INCB00928); or combinations thereof..

For treating cancer and other proliferative diseases, compounds described herein can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti -proliferative agents. Compounds described herein can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g. , gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amidox, amsacrine, anastrozole, aphidicolon, arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab, bexarotene, baricitinib, bendamustine, bicalutamide, bleomycin, bortezombi, bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan oral, calusterone, camptosar, capecitabine, carboplatin, carmustine, cediranib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dacomitinib, dactinomycin, dalteparin sodium, dasatinib, dactinomycin, daunorubicin, decitabine, degarelix, denileukin, denileukin diftitox, deoxycoformycin, dexrazoxane, didox, docetaxel, doxorubicin, droloxafme, dromostanolone propionate, eculizumab, enzalutamide,

epidophyllotoxin, epirubicin, epothilones, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, idelalisib, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lonafamib, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mithramycin, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, navelbene, necitumumab, nelarabine, neratinib, nilotinib, nilutamide, niraparib, nofetumomab, oserelin, oxaliplatin, paclitaxel, pamidronate, panitumumab, panobinostat, pazopanib, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pilaralisib, pipobroman, plicamycin, ponatinib, porfimer, prednisone, procarbazine, quinacrine, ranibizumab, rasburicase, regorafenib, reloxafme, revlimid, rituximab, rucaparib, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, tegafur, temozolomide, teniposide, testolactone, tezacitabine, thalidomide, thioguanine, thiotepa, tipifarnib, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, triapine, trimidox, triptorelin, uracil mustard, valrubicin, vandetanib, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, veliparib, talazoparib, and zoledronate.

Cancer cell growth and survival can be impacted by dysfunction in multiple signaling pathways. Thus, it is useful to combine different enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug -resistance arising in a cell population, and/or reduce the toxicity of treatment. One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, immune- oncology agents, metabolic enzyme inhibitors, chemokine receptor inhibitors, and phosphatase inhibitors, as well as targeted therapies such as Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, c-Kit, IGF-1R, RAF, FAR, CDK2, and CDK4/6 kinase inhibitors such as, for example, those described in WO 2006/056399 can be used in combination with the treatment methods and regimens of the present disclosure for treatment of cancers and solid tumors. Other agents such as therapeutic antibodies can be used in combination with the treatment methods and regimens of the present disclosure for treatment of cancers and solid tumors. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.

The treatment methods as disclosed herein can be used in combination with one or more other enzyme/protein/receptor inhibitors therapies for the treatment of diseases, such as cancer and other diseases or disorders described herein. For example, the treatment methods and regimens of the present disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, BCL2, CDK2, CDK4/6, TGF- R, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IDH2, IGF-1R, IR-R, PDGFoR, PDGF R, PI3K (alpha, beta, gamma, delta, and multiple or selective), CSF1R, KIT, FLK-II,

KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, PARP, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Non-limiting examples of inhibitors that can be combined with the treatment methods and regimens of the present disclosure for treatment of cancer include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., pemigatinib (INCB54828), INCB62079), an EGFR inhibitor (also known as ErB-1 or HER-1; e.g. erlotinib, gefitinib, vandetanib, orsimertinib, cetuximab, necitumumab, or panitumumab), a VEGFR inhibitor or pathway blocker (e.g. bevacizumab, pazopanib, sunitinib, sorafenib, axitinib, regorafenib, ponatinib, cabozantinib, vandetanib, ramucirumab, lenvatinib, ziv-aflibercept), a PARP inhibitor (e.g. olaparib, rucaparib, veliparib or niraparib), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib, itacitinib (INCB39110), an LSDl inhibitor (e.g., INCB59872 and INCB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50465 and INCB50797), a PI3K-gamma inhibitor such as PI3K-gamma selective inhibitor, a Pirn inhibitor (e.g., INCB53914), a CSF1R inhibitor, a TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer), an adenosine receptor antagonist (e.g., A2a/A2b receptor antagonist), an HPK1 inhibitor, a chemokine receptor inhibitor (e.g. CCR2 or CCR5 inhibitor), a SHP1/2 phosphatase inhibitor, a histone deacetylase inhibitor (HD AC) such as an HDAC8 inhibitor, an angiogenesis inhibitor, an interleukin receptor inhibitor, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors such as

INCB54329 and INCB57643), c-MET inhibitors (e.g., capmatinib), an anti-CD19 antibody (e.g, tafasitamab), an ALK2 inhibitor (e.g, INCB00928); or combinations thereof.

In some embodiments, the treatment methods described herein are combined with administration of a PI3K5 inhibitor. In some embodiments, the treatment methods described herein are combined with administration of a JAK inhibitor. In some embodiments, the treatment methods described herein are combined with administration of a JAK1 or JAK2 inhibitor (e.g., baricitinib or ruxolitinib). In some embodiments, the treatment methods described herein are combined with administration of a JAK1 inhibitor. In some

embodiments, the treatment methods described herein are combined with administration of a JAK1 inhibitor, which is selective over JAK2.

Example antibodies that can be administered in combination therapy include, but are not limited to, trastuzumab (e.g, anti-HER2), ranibizumab (e.g, anti-VEGF-A), bevacizumab (AVASTIN™, e.g., anti-VEGF), panitumumab (e.g, anti-EGFR), cetuximab (e.g, anti- EGFR), rituxan (e.g, anti-CD20), and antibodies directed to c-MET.

One or more of the following agents may be administered to a patient in combination with the treatment methods of the present disclosure and are presented as a non-limiting list: a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662,

IRESSA™(gefitinib), TARCEVA™ (erlotinib), antibodies to EGFR, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™ (oxaliplatin), pentostatine, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L- asparaginase, teniposide 17.alpha.-ethinylestradiol, di ethyl stilbestrol, testosterone,

Prednisone, Fluoxymesterone, Dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chi orotriani sene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesteroneacetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafme, droloxafme, hexamethylmelamine, avastin, HERCEPTIN™

(trastuzumab), BEXXAR™ (tositumomab), VELCADE™ (bortezomib), ZEVALIN™ (ibritumomab tiuxetan), TRISENOX™ (arsenic trioxide), XELODA™ (capecitabine), vinorelbine, porfimer, ERBITUX™ (cetuximab), thiotepa, altretamine, melphalan, trastuzumab, lerozole, fulvestrant, exemestane, ifosfomide, rituximab, C225 (cetuximab), Campath (alemtuzumab), clofarabine, cladribine, aphidicolon, rituxan, sunitinib, dasatinib, tezacitabine, Smll, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, and MDL-101,731.

The treatment methods and regimens of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumor-targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccine, monoclonal antibody, bispecific or multi specific antibody, antibody drug conjugate, adoptive T cell transfer, Toll receptor agonists, RIG-I agonists, oncolytic virotherapy and immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor, PI3K5 inhibitor and the like. The compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutic agent. Examples of chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epacadostat, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine,

meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.

Additional examples of chemotherapeutics include proteosome inhibitors ( e.g ., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.

Example steroids include corticosteroids such as dexamethasone or prednisone.

Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVAC™), nilotinib, dasatinib, bosutinib, and ponatinib, and pharmaceutically acceptable salts. Other example suitable Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, and U.S. Ser. No. 60/578,491.

Example suitable Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib, maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215, and their pharmaceutically acceptable salts. Other example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO

03/037347, WO 03/099771, and WO 04/046120.

Example suitable RAF inhibitors include dabrafenib, sorafenib, and vemurafenib, and their pharmaceutically acceptable salts. Other example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.

Example suitable FAR inhibitors include VS-4718, VS-5095, VS-6062, VS-6063, BI853520, and GSK2256098, and their pharmaceutically acceptable salts. Other example suitable FAR inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO

00/053595, and WO 01/014402.

Example suitable CDK4/6 inhibitors include palbociclib, ribociclib, trilaciclib, lerociclib, and abemaciclib, and their pharmaceutically acceptable salts. Other example suitable CDK4/6 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 09/085185, WO 12/129344, WO 11/101409, WO 03/062236, WO 10/075074, and WO 12/061156.

In some embodiments, the compounds of the disclosure can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.

In some embodiments, the treatment methods of the disclosure can be used in combination with a chemotherapeutic in the treatment of cancer, and may improve the treatment response as compared to the response to the chemotherapeutic agent alone, without exacerbation of its toxic effects. In some embodiments, the treatment methods of the disclosure can be used in combination with a chemotherapeutic provided herein. For example, additional pharmaceutical agents used in the treatment of multiple myeloma, can include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAR kinase inhibitors. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM). Additive or synergistic effects are desirable outcomes of combining treatment methods of the present disclosure with an additional agent.

The agents can be combined with Compound 1 and/or antibody that binds to human PD-1 or human PD-L1, or antigen -binding fragment thereof, of the present treatment methods in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with the treatment methods of the disclosure where the dexamethasone is administered intermittently as opposed to continuously.

The treatment methods described herein can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF. The treatment methods described herein can be used in combination with a vaccination protocol for the treatment of cancer. In some embodiments, the tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV),

Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the treatment methods and regimens of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself. In some embodiments, the treatment methods described herein can be combined with dendritic cells immunization to activate potent anti-tumor responses.

The treatment methods and regimens of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor expressing effectors cells to tumor cells. The treatment methods and regimens of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.

In some further embodiments, the treatment methods of the disclosure are combined with administration of other therapeutic agents to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant. The treatment methods and regimens of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.

In some embodiments, the compounds described herein can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an

immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

Suitable antiviral agents contemplated for use in combination with compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil

[bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fluoro-cytidene); DAPD, ((- )-beta-D-2, 6, -diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.

Suitable agents for use in combination with compounds described herein for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies,

immunotherapies or radiation therapy. Compounds described herein may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors. Suitable examples are anti -estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds described herein. These include anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g.

abiraterone).

The compounds described herein may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c- Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Aik (or EML4-ALK) include crizotinib. Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti -angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib

Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds described herein include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.

Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds described herein. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.

Other suitable agents for use in combination with compounds described herein include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).

Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine,

cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

Other suitable agents for use in combination with compounds described herein include steroids including 17 alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, and

medroxy proge steroneacetate .

Other suitable agents for use in combination with compounds described herein include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the“Dartmouth regimen,” which consists of DTIC,

BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compounds described herein may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in.

Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate,

pentostatine, and gemcitabine.

Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara- C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.

Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole,

capecitabine, reloxafme, cyclophosphamide, ifosamide, and droloxafme.

Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.

Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab

(Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB, PD-L1 and PD-1 antibodies, or antibodies to cytokines (IL-10, TGF-b, etc.).

Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4. Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.

Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.

In some embodiments, compounds described herein can be used in combination with immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD 122, CD96, CD73, CD47, 0X40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3 (e g.,

INCAGN2385), TIM3 (e g., INCB2390), VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40 (e.g., INCAGN1949), GITR (e.g.,

INCAGN1876) and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.

In some embodiments, the inhibitor of an immune checkpoint molecule is a small molecule PD-L1 inhibitor. In some embodiments, the small molecule PD-L1 inhibitor has an IC50 less than 1 mM, less than 100 nM, less than 10 nM or less than 1 nM in a PD-L1 assay described in US Patent Publication Nos. US 20170107216, US 20170145025, US

20170174671, US 20170174679, US 20170320875, US 20170342060, US 20170362253, and US 20180016260, each of which is incorporated by reference in its entirety for all purposes.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti -PD-1 monoclonal antibody. In some embodiments, the anti -PD-1 monoclonal antibody is MGA012, nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, ipilumimab or AMP -224. In some embodiments, the anti- PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti- PD1 antibody is pembrolizumab. In some embodiments, the anti-PDl antibody is nivolumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012 (retifanlimab). In some embodiments, the anti-PDl antibody is SHR-1210. Other anti-cancer agent(s) include antibody therapeutics such as 4- IBB (e.g. urelumab, utomilumab).

In some embodiments, the compounds of the disclosure can be used in combination with INCB086550.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is MPDL3280A or MEDI4736.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.

In some embodiments, the inhibitor of an immune checkpoint molecule is an agonist of 0X40, e.g., 0X40 agonist antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS- 986178. In some embodiments, the OX40L fusion protein is MEDI6383.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD19, e.g., an anti-CD19 antibody. In some embodiments, the anti-CD19 antibody is tafasitamab.

The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, 0X40, TIM3, LAG3, CD137, ICOS, CD3 or TGFp receptor.

In some embodiments, the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO 1, TDO, or arginase. Examples of IDO 1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.

Compounds of the present disclosure can be used in combination with one or more immune checkpoint inhibitors for the treatment of diseases, such as cancer or infections. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CBL-B, CD20, CD28, CD40, CD70, CD 122, CD96, CD73, CD47, CDK2, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, HPK1, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, TLR (TLR7/8), TIGIT, CD112R, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.

In some embodiments, the compounds provided herein can be used in combination with one or more agonists of immune checkpoint molecules, e.g., 0X40, CD27, GITR, and CD137 (also known as 4-1BB).

In some embodiments, the inhibitor of an immune checkpoint molecule is anti -PD 1 antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1 or PD-L1, e.g., an anti-PD-1 or anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-1 or anti-PD-Ll antibody is nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, atezolizumab, avelumab, tislelizumab, spartalizumab (PDR001), cetrelimab (JNJ-63723283), toripalimab (JS001), camrelizumab (SHR-1210), sintilimab (IBI308), AB122 (GLS-010), AMP-224, AMP-514/MEDI-0680, BMS936559, JTX-4014, BGB-108, SHR-1210, MEDI4736, FAZ053, BCD-100, KN035, CSIOOI, BAT 1306, LZM009, AK105, HLX10, SHR-1316, CBT-502 (TQB2450), A167 (KL-A167), STI-A101 (ZKAB001), CK-301, BGB-A333, MSB-2311, HLX20, TSR-042, or LY3300054. In some embodiments, the inhibitor of PD-1 or PD-L1 is one disclosed in U.S. Pat. Nos. 7,488,802, 7,943,743, 8,008,449, 8,168,757, 8,217, 149, or 10,308,644; U.S. Publ. Nos. 2017/0145025, 2017/0174671, 2017/0174679, 2017/0320875, 2017/0342060,

2017/0362253, 2018/0016260, 2018/0057486, 2018/0177784, 2018/0177870, 2018/0179179, 2018/0179201, 2018/0179202, 2018/0273519, 2019/0040082, 2019/0062345, 2019/0071439, 2019/0127467, 2019/0144439, 2019/0202824, 2019/0225601, 2019/0300524, or

2019/0345170; or PCT Pub. Nos. WO 03042402, WO 2008156712, WO 2010089411, WO 2010036959, WO 2011066342, WO 2011159877, WO 2011082400, or WO 2011161699, which are each incorporated herein by reference in their entirety. In some embodiments, the inhibitor of PD-L1 is INCB086550.

In some embodiments, the antibody is an anti -PD-1 antibody, e.g., an anti -PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, cetrelimab, toripalimab, sintilimab, AB122, AMP-224, JTX-4014, BGB-108, BCD-100, BAT1306, LZM009, AK105, HLX10, or TSR-042. In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, cetrelimab, toripalimab, or sintilimab. In some embodiments, the anti-PD-1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 antibody is nivolumab. In some embodiments, the anti-PD-1 antibody is cemiplimab. In some embodiments, the anti-PD-1 antibody is spartalizumab. In some embodiments, the anti-PD-1 antibody is camrelizumab. In some embodiments, the anti-PD-1 antibody is cetrelimab. In some embodiments, the anti-PD-1 antibody is toripalimab. In some embodiments, the anti-PD-1 antibody is sintilimab. In some embodiments, the anti-PD-1 antibody is AB122. In some embodiments, the anti-PD-1 antibody is AMP -224. In some embodiments, the anti-PD-1 antibody is JTX-4014. In some embodiments, the anti-PD-1 antibody is BGB-108. In some embodiments, the anti-PD-1 antibody is BCD-100. In some embodiments, the anti-PD-1 antibody is BAT1306. In some embodiments, the anti-PD-1 antibody is LZM009. In some embodiments, the anti-PD-1 antibody is AK105. In some embodiments, the anti-PD-1 antibody is HLX10. In some embodiments, the anti-PD-1 antibody is TSR-042. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PDl antibody is SHR-1210. Other anti-cancer agent(s) include antibody therapeutics such as 4- 1BB ( e.g ., urelumab, utomilumab). In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is atezolizumab, avelumab, durvalumab, tislelizumab, BMS-935559, MEDI4736, atezolizumab (MPDL3280A;also known as RG7446), avelumab (MSB0010718C), FAZ053, KN035, CSIOOI, SHR-1316, CBT-502, A167, STI-A101, CK-301, BGB-A333, MSB-2311, HLX20, or LY3300054. In some embodiments, the anti-PD-Ll antibody is atezolizumab, avelumab, durvalumab, or tislelizumab. In some embodiments, the anti-PD-Ll antibody is atezolizumab. In some embodiments, the anti-PD-Ll antibody is avelumab. In some embodiments, the anti-PD-Ll antibody is durvalumab. In some embodiments, the anti-PD-Ll antibody is tislelizumab. In some embodiments, the anti-PD-Ll antibody is BMS-935559. In some embodiments, the anti-PD-Ll antibody is MEDI4736. In some embodiments, the anti-PD-Ll antibody is FAZ053. In some embodiments, the anti-PD-Ll antibody is KN035. In some embodiments, the anti-PD-Ll antibody is CSIOOI. In some embodiments, the anti-PD-Ll antibody is SHR- 1316. In some embodiments, the anti-PD-Ll antibody is CBT-502. In some embodiments, the anti-PD-Ll antibody is A167. In some embodiments, the anti-PD-Ll antibody is STI- A101. In some embodiments, the anti-PD-Ll antibody is CK-301. In some embodiments, the anti-PD-Ll antibody is BGB-A333. In some embodiments, the anti-PD-Ll antibody is MSB-2311. In some embodiments, the anti-PD-Ll antibody is HLX20. In some

embodiments, the anti-PD-Ll antibody is LY3300054.

In some embodiments, the inhibitor of an immune checkpoint molecule is a small molecule that binds to PD-L1, or a pharmaceutically acceptable salt thereof. In some embodiments, the inhibitor of an immune checkpoint molecule is a small molecule that binds to and internalizes PD-L1, or a pharmaceutically acceptable salt thereof. In some

embodiments, the inhibitor of an immune checkpoint molecule is a compound selected from those in US 2018/0179201, US 2018/0179197, US 2018/0179179, US 2018/0179202, US 2018/0177784, US 2018/0177870, US Ser. No. 16/369,654 (filed Mar. 29, 2019), and US Ser. No. 62/688,164, or a pharmaceutically acceptable salt thereof, each of which is incorporated herein by reference in its entirety.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of KIR, TIGIT, LAIR1, CD 160, 2B4 and TGFR beta.

In some embodiments, the inhibitor is MCLA-145. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, INCAGN2385, or eftilagimod alpha (IMP321).

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD73. In some embodiments, the inhibitor of CD73 is oleclumab.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIGIT. In some embodiments, the inhibitor of TIGIT is OMP-31M32.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of VISTA. In some embodiments, the inhibitor of VISTA is TNJ-61610588 or CA-170.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of B7-H3. In some embodiments, the inhibitor of B7-H3 is enoblituzumab, MGD009, or 8H9.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of KIR. In some embodiments, the inhibitor of KIR is lirilumab or IPH4102.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of A2aR. In some embodiments, the inhibitor of A2aR is CPI-444.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TGF-beta. In some embodiments, the inhibitor of TGF-beta is trabedersen, galusertinib, or M7824.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PI3K-gamma. In some embodiments, the inhibitor of PI3K-gamma is IPI-549.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD47. In some embodiments, the inhibitor of CD47 is Hu5F9-G4 or TTI-621.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD73. In some embodiments, the inhibitor of CD73 is MED 19447.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD70. In some embodiments, the inhibitor of CD70 is cusatuzumab or BMS-936561.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.

In some embodiments, the agonist of an immune checkpoint molecule is an agonist of 0X40, CD27, CD28, GITR, ICOS, CD40, TLR7/8, and CD137 (also known as 4-1BB).

In some embodiments, the agonist of CD137 is urelumab. In some embodiments, the agonist of CD 137 is utomilumab.

In some embodiments, the agonist of an immune checkpoint molecule is an inhibitor of GITR. In some embodiments, the agonist of GITR is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, MEDI1873, or MEDI6469.In some embodiments, the agonist of an immune checkpoint molecule is an agonist of 0X40, e.g., 0X40 agonist antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is INCAGN01949, MEDI0562 (tavolimab), MOXR-0916, PF-04518600,

GSK3174998, BMS-986178, or 9B12.. In some embodiments, the OX40L fusion protein is MEDI6383.

In some embodiments, the agonist of an immune checkpoint molecule is an agonist of CD40. In some embodiments, the agonist of CD40 is CP-870893, ADC-1013, CDX-1140, SEA-CD40, R07009789, JNJ-64457107, APX-005M, or Chi Lob 7/4.

In some embodiments, the agonist of an immune checkpoint molecule is an agonist of ICOS. In some embodiments, the agonist of ICOS is GSK-3359609, JTX-2011, or MEDI- 570.

In some embodiments, the agonist of an immune checkpoint molecule is an agonist of CD28. In some embodiments, the agonist of CD28 is theralizumab.

In some embodiments, the agonist of an immune checkpoint molecule is an agonist of CD27. In some embodiments, the agonist of CD27 is varlilumab.

In some embodiments, the agonist of an immune checkpoint molecule is an agonist of TLR7/8. In some embodiments, the agonist of TLR7/8 is MEDI9197.

The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, 0X40, TIM3, LAG3, CD137, ICOS, CD3 or TGFp receptor. In some embodiments, the bispecific antibody binds to PD-1 and PD-L1. In some

embodiments, the bispecific antibody that binds to PD-1 and PD-L1 is MCLA-136. In some embodiments, the bispecific antibody binds to PD-L1 and CTLA-4. In some embodiments, the bispecific antibody that binds to PD-L1 and CTLA-4 is AK104. In some embodiments, the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO 1, TDO, or arginase. Examples of IDO 1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196. Inhibitors of arginase inhibitors include INCBl 158.

As provided throughout, the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.

abiraterone).

The compounds described herein may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c- Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Aik (or EML4-ALK) include crizotinib.

Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti -angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib

Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds described herein include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression. Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds described herein. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.

medroxy proge steroneacetate .

pentostatine, and gemcitabine.

Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole,

capecitabine, reloxafme, cyclophosphamide, ifosamide, and droloxafme.

Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab

Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.

Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.

The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin. Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.

Pharmaceutical Formulations and Dosage Forms

When employed as pharmaceuticals, compounds described herein can be administered in the form of pharmaceutical compositions which refers to a combination of one or more compounds described herein, and at least one pharmaceutically acceptable carrier or excipient. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical

(including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

This disclosure also includes pharmaceutical compositions which contain, as the active ingredient, one or more compounds described herein in combination with one or more pharmaceutically acceptable carriers or excipients. In making the compositions described herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is suitable for topical administration.

In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified

microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w.

In some embodiments, the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some

embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PHI 02™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M ( e.g ., Methocel K4 M

Premier™) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel K00LV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g, Poly ox WSR 1105™).

In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.

The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable

pharmaceutical excipient.

The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g, at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration. For example, suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good

Manufacturing Practice regulations of the U.S. Food and Drug Administration. The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

The therapeutic dosage of a compound of the present invention can vary according to, e.g ., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a

pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g, hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of one or more compounds described herein. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present disclosure.

The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the compounds, or compositions as described herein can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g ., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g. , glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g. , glycerol, hydroxy ethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, e.g. , 100 g which are optionally associated with instructions for the treatment of the select indication, e.g. , psoriasis or other skin condition.

The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of

administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of the compounds in a

pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, compounds of the present disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral

administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.

Compounds described herein can also be formulated in combination with one or more additional active ingredients, which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like. Labeled Compounds and Assay Methods

Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo , for localizing and quantitating the FGFR enzyme in tissue samples, including human, and for identifying FGFR enzyme ligands by inhibition binding of a labeled compound. Substitution of one or more of the atoms of the compounds of the present disclosure can also be useful in generating differentiated ADME (Adsorption, Distribution, Metabolism and Excretion). Accordingly, the present invention includes FGFR binding assays that contain such labeled or substituted compounds.

The present invention further includes isotopically-labeled compounds of the invention. An“isotopically” or“radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to ²H (also written as D for deuterium), ³H (also written as T for tritium), ^UC, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵0, ¹⁷0, ¹⁸0, ¹⁸F, ³⁵S, ³⁶C1, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro FGFR enzyme labeling and competition assays, compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵1 , ¹³¹I, or ³⁵S will generally be most useful. For radio-imaging applications ^UC, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br will generally be most useful. One or more hydrogen atoms in a compound of the present disclosure can be replaced by deuterium atoms (e.g., one or more hydrogen atoms of a C_1-6 alkyl group of Formula (I) can be optionally substituted with deuterium atoms, such as -CD3 being substituted for -CFE). In some embodiments, alkyl groups in Formula (I) can be perdeuterated.

One or more constituent atoms of the compounds presented herein can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms. In some embodiments, all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.

Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton- Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can be used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays.

Substitution with heavier isotopes, such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances (see e.g., A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210; R. Xu et. al. J. Label Compd.

Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolism sites may afford one or more of the therapeutic advantages.

The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro adenosine receptor labeling and competition assays, compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵I, ^mI or ³⁵S can be useful. For radio-imaging applications ^UC, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br can be useful.

It is understood that a“radio-labeled” or“labeled compound” is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of ³H, ¹⁴C, ¹²⁵1 , ³⁵S and ⁸²Br.

Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.

The present disclosure can further include synthetic methods for incorporating radio isotopes into compounds of the disclosure. Synthetic methods for incorporating radio isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of disclosure.

A radio-labeled compound of the invention can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio-labeled compound of the invention to the FGFR4 enzyme. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the FGFR4 enzyme directly correlates to its binding affinity.

A labeled compound of the invention can be used in a screening assay to identify and/or evaluate compounds. For example, a newly synthesized or identified compound {i.e., test compound) which is labeled can be evaluated for its ability to bind an FGFR protein (e.g., FGFR3) by monitoring its concentration variation when contacting with the FGFR, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a FGFR protein (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the FGFR protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.

Kits

The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of FGFR-associated diseases or disorders (e.g., cancer), obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non- critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of one or more FGFR’s as described below.

EXAMPLES

Experimental procedures for compounds of the invention are provided below. All the starting materials are commercially available or readily synthezied according to procedures known in the art. Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g.“Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem ., 4, 295 (2002);“Optimizing Preparative LC- MS Configurations and Methods for Parallel Synthesis Purification”, K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem ., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem ., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ Cis 5 pm particle size, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL/minute.

Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse- phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:

pH = 2 purifications: Waters Sunfire™ Cis 5 pm particle size, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem ., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute. pH = 10 purifications: Waters XBridge Cis 5 pm particle size, 19 x 100 mm column, eluting with mobile phase A: 0.15% MEOH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute. Example 1. l-(3-(l-Methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)piperidin- 3-ol

Step 1. 5-Chloro-3-iodo-1H-pyrazolo[4,3-b]pyridine

A solution of 5-chloro-1H-pyrazolo[4,3-b ]pyridine (10 g, 65 mmol) in DMF (60 mL) was treated with l-iodopyrrolidine-2,5-dione (14.6 g, 65 mmol). The reaction was warmed to 80°C and stirred for 1 h. The reaction mixture was then cooled to r.t., poured into water (300 mL) and stirred for 10 min. The resulting solid was filtered, collected and was used in the next step without further purification. LC-MS calculated for C6H4CIIN3 (M+H)⁺: m/z = 279.9; found 279.9.

Step 2. 5-Chloro-3-iodo-l-(4-methoxybenzyl)-1H-pyrazolo[ 4, 3-b ] pyridine

A solution of 5-chloro-3-iodo-1H-pyrazolo[4,3-b ]pyridine (13g, 46.5 mmol) in DMF

(60 mL) was treated with l-(chloromethyl)-4-methoxybenzene (7.60 ml, 55.8 mmol) and K2CO3 (7.71 g, 55.8 mmol). The reaction mixture was stirred at 90°C for 1 h. The mixture was then cooled to r.t., diluted with water and extracted with EtOAc three times. The combined organic phases were washed with sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C14H12CIIN3O (M+H)⁺: m/z = 400.0; found 400.0. Step 3. 5-Chloro-l-(4-methoxybenzyl)-3-( l -methyl-1H-pyrazol-4-yl)-1H-pyrazolo[ 4,3- b] pyridine

A solution of 5-chloro-3-Iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b ]pyridine (18.58 g, 46.5 mmol) in 1,4-dioxane (141 mL) and water (14 mL) was treated with 1-methyl- 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-1H-pyrazole (9.68 g, 46.5 mmol), potassium phosphate (19.74 g, 93 mmol), and [dichloro[l, T- bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (3.80 g, 4.65 mmol). The reaction mixture was degassed (by evacuation and backfilling with nitrogen) and stirred at 80°C for 8 h. The reaction mixture was then cooled to r.t., diluted with EtOAc, washed sequentially with water and sat. aq. NaCl, and dried over Na2S04. The organic phases were filtered and concentrated to dryness. The residue was purified by silica gel

chromatography to afford the desired product. LC-MS calculated for C ixHi-CINsO (M+H)⁺: m/z = 354.1; found 354.1.

Step 4. l-(3-(l-Methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)piperidin-3-ol

A solution of 5-chloro-l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-b ]pyridine (20 mg, 0.056 mmol) in 1,4-dioxane (0.5 mL) was treated with piperidin-3-ol (5.7 mg, 0.057 mmol), CS2CO3 (35.7 mg, 0.11 mmol), and chloro(2- dicy clohexylphosphino-2’ ,6’ -dii sopropoxy- 1, 1’ -biphenyl) [2-(2’ -amino- 1,1’- biphenyl)]palladium(II) (Ruphos-Pd G2, 3.9 mg, 5.65 pmol). The reaction mixture was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was then concentrated and dissolved in 0.5 mL of TFA. The mixture was heated at 100°C for 1 h before concentration and purification by prep-LCMS (XB ridge Cl 8 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for Ci5Hi9N60(M+H)⁺: m/z = 299.2; found 299.2. Example 2. 3-(l-Methyl-1H-pyrazol-4-yl)-5-(l-(trifluoromethyl)-5,6- dihydroimidazo [1 ,5-a] pyrazin-7(8H)-yl)- 1H-pyrazolo [4,3-b] pyridine

This compound was prepared according to the procedure described in Example 1, using l-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine instead of piperidin-3-ol. The product was isolated as the TFA salt. LC-MS calculated for C₁₇H₁₆N₈F₃ (M+H)⁺ : m/z = 389.1; found 389.2.

Example 3. 5-(6,7-Dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl)-3-(l-methyl-1H-pyrazol- 4-yl)- 1H-pyr azolo [4,3-b] pyridine

This compound was prepared according to the procedure described in Example 1, using 4,5,6,7-tetrahydropyrazolo[l,5-a]pyrimidine instead of piperidin-3-ol. The product was isolated as the TFA salt. LC-MS calculated for C₁₆H₁₇N₈ (M+H)⁺ : m/z = 321.1; found 321.2.

Example 4. 3-Methyl-8-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- 3,8-diazabicyclo [3.2.1] octan-2-one

Step 1. 8-(l -(4-Methoxybenzyl)-3-( l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5- yl)-3, 8-diazabicyclo[ 3.2.1 ] octan-2 -one

A solution of 5-chloro-l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-b ]pyridine (Example 1, Step 3; 20 mg, 0.056 mmol) in 1,4-dioxane (0.5 mL) was treated with 3,8-diazabicyclo[3.2.1]octan-2-one (7 mg, 0.057 mmol), CS2CO3 (0.11 mmol), and chloro(2-dicy clohexylphosphino-2’ , 6’ -dii sopropoxy- 1,1’ -biphenyl) [2-(2’ -amino- 1, 1'-biphenyl)]palladium(II) (Ruphos-Pd G2, 3.9 mg, 5.65 pmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was cooled, concentrated and purified by silica gel chromatography to afford the desired product. LCMS calculated for C24H26N702(M+H)⁺: m/z = 444.2; found 444.2.

Step 2. 3-Methyl-8-(3-( l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5-yl)-3, 8- diazabicyclo[ 3.2.1 ] octan-2-one

A solution of 8-(l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-b ]pyridin-5-yl)-3,8-diazabicyclo[3.2.1]octan-2-one (10 mg, 0.022 mmol) in DMF (0.5 mL) was treated with NaH (60 % dispersion in mineral oil, 1.1 mg, 0.029 mmol) at 0°C. The reaction mixture was stirred at this temperature for 30 min before Mel (2 mΐ, 0.029 mmol) was added. The mixture was warmed to rt and stirred for another 30 min. After completion, the reaction was diluted with EtOAc and water. The mixture was extracted with EtOAc 2 times. The organic phases were combined, washed with water and sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was then dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was cooled, concentrated and purified by prep-LCMS (XB ridge Cl 8 column, eluting with a gradient of

acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for Ci7H2oN70(M+H)⁺: m/z = 338.2; found 338.2. Example 5. 3-Isopropyl-l-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3- b]pyridin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 1, using 3-isopropyl-l-methylpiperazin-2-one instead of piperidin-3-ol. LC-MS calculated for C18H24N7O (M+H)⁺ : m/z = 354.2; found 354.2.

Example 6. 3-Ethyl-l-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3- b]pyridin-5-yl)piperazin-2-one

Step 1. 4-(l -(4-Methoxybenzyl)-3-( l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5- yl)-l-methylpiperazin-2-one

A solution of 5-chloro- 1 -(4-methoxybenzyl)-3-( l -methyl - 1H-pyrazol-4-yl )-!//- pyrazolo[4,3-£]pyridine (Example 1, step 3; lg, 2.83 mmol) in 1,4-dioxane (10 mL) was treated with l-methylpiperazin-2-one (0.387 g, 3.39 mmol), CS2CO3 (2.3 g, 7.07 mmol), and chloro(2-dicy clohexylphosphino-2’ , 6’ -dii sopropoxy- 1,1’ -biphenyl) [2-(2’ -amino- 1,1’- biphenyl)]palladium(II) (Ruphos-Pd G2, 0.198 g, 0.28 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was cooled, concentrated and purified by silica gel chromatography to afford the desired product. LCMS calculated for C23H2₆N702(M+H)⁺: m/z = 432.2; found 432.2.

Step 2. 3-Ethyl- l-methyl-4-( 3-(l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5- yl)piperazin-2-one

A solution of 4-(l-(4-methoxybenzyl)-3-(l -methyl- 1H-pyrazol-4-yl)- IH- pyrazolo[4,3-b ]pyridin-5-yl)-l-methylpiperazin-2-one (20 mg, 0.046 mmol) in THF was treated with LDA (2.0 M THF solution, 46 mL, 0.092 mmol) at -78 °C. The resulting solution was stirred at the same temperature for 20 min before ethyl iodide (7 mΐ, 0.092 mmol) was added. The reaction was slowly warmed up to r.t. and stirred for additional 20 min. After completion, the reaction was treated with sat. aq. MHO, and extracted with EtOAc. The organic phases were combined, washed with water and sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was then dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was concentrated and purified by prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). Peak 1 was obtained as the TFA salt of the titled compound. LCMS calculated for Ci7H22N70(M+H)⁺: m/z = 340.2; found 340.2.

Example 7. 3,3-Diethyl-l-methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ] pyr idin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6. The reaction was purified by prep-LCMS (XBridge Cl 8 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). Peak 2 was obtained as the TFA salt of the titled compound. LCMS calculated for Ci9H2₆N70(M+H)⁺: m/z = 368.2; found 368.2. Example 8. 3-Benzyl-l-methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ] pyr idin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6, using (bromomethyl)benzene instead of ethyl iodide in step 2. The product was isolated as the TFA salt. LC-MS calculated for C22H24N7O (M+H)⁺ : m/z = 402.2; found 402.2.

Example 9. 3-(Cyclopropylmethyl)-l-methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo [4,3 -b] pyridin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6, using (iodomethyl)cyclopropane instead of ethyl iodide in step 2. The product was isolated as the TFA salt. LC-MS calculated for C19H24N7O (M+H)⁺ : m/z = 366.2; found 366.2.

Example 10. l-Methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- 3-(tetrahydro-2H -pyran-4-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6, using 4-iodotetrahydro-2H-pyran instead of ethyl iodide in step 2. The product was isolated as the TFA salt. LC-MS calculated for C20H26N7O2 (M+H)⁺ : m/z = 396.2; found 396.2. Example 11. l-Methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- 3-(pyridin-4-ylmethyl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6, using 4- 4-(bromomethyl)pyridine hydrobromide instead of ethyl iodide in step 2. The product was isolated as the TFA salt. LC-MS calculated for C21H23N8O (M+H)⁺ : m/z = 403.2; found 403.2.

Example 12. l-Methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- 3-(l-phenylethyl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6, using 4- 4 (l-bromoethyl)benzene instead of ethyl iodide in step 2. The product was isolated as the TFA salt. LC-MS calculated for C23H26N7O (M+H)⁺ : m/z = 416.2; found 416.2. Example 13. 3-Cyclopropyl-l-methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ] pyr idin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 6, using iodocyclopropane instead of ethyl iodide in step 2. The product was isolated as the TFA salt. LC-MS calculated for C18H22N7O (M+H)⁺ : m/z = 352.2; found 352.2.

Example 14. l-Cyclopropyl-3-methyl-4-(3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ] pyr idin-5-yl)piperazin-2-one

Step 1. l-Cyclopropyl-4-( l -( 4-methoxybenzyl)-3-( l -methyl- IH-pyr azol-4-yl)-1H- pyrazolo[ 4, 3-b ]pyridin-5-yl)piperazin-2-one

A solution of 5-chloro- 1 -(4-methoxybenzyl)-3-( l -methyl - 1H-pyrazol-4-yl )-!//- pyrazolo[4,3-£]pyridine (Example 1, step 3; 500mg, 1.42 mmol) in 1,4-dioxane (5 mL) was treated with l-cyclopropylpiperazin-2-one (237 mg, 1.7 mmol), CS2CO3 (1.15 g, 3.5 mmol), and chloro(2-dicyclohexylphosphino-2’ ,6’ -diisopropoxy- 1,1’ -biphenyl)[2-(2’ -amino- 1,1’- biphenyl)]palladium(II) (Ruphos-Pd G2, 99 mg, 0.14 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was cooled, concentrated and purified by silica gel chromatography to afford the desired product. LCMS calculated for C₂₅H₂₈N₇0₂(M+H)⁺: m/z = 458.2; found 458.2. Step 2. 1-Cyclopropyl-3-methyl-4-(3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin- 5-yl)piperazin-2-one

A solution of l-cyclopropyl-4-(l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)piperazin-2-one (20 mg, 0.043 mmol) in THF was treated with LDA (2.0 M THF solution, 46 mL, 0.092 mmol) at -78 °C. The resulting solution was stirred at this temperature for 20 min before methyl iodide (8 mΐ, 0.092 mmol) was added.

The reaction was slowly warmed up to r.t. and stirred for additional 20 min. After completion, the reaction was treated with sat. aq. NH₄Cl, and extracted with EtOAc. The organic phases were combined, washed with water and sat. aq. NaCl, dried with Na2SO ₄, filtered and concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was cooled, concentrated and purified by prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). Peak 1 was obtained as the TFA salt of the titled compound. LCMS calculated for C₁₈H₂₂N₇O(M+H)⁺: m/z = 352.2; found 352.2. Example 15. 1,3,6-Trimethyl-4-(3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ] pyridin-5-yl)piperazin-2-one

Step 1. 4-(l -(4-Methoxybenzyl)-3-( l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5- yl)-l, 6-dimethylpiperazin-2-one

A solution of 5-chloro-l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-b ]pyridine (Example 1, step 3; 500mg, 1.42 mmol) in 1,4-dioxane (5 mL) was treated with l,6-dimethylpiperazin-2-one (237 mg, 1.7 mmol), CS2CO3 (1.15 g, 3.5 mmol), and chloro(2-dicyclohexylphosphino-2’ ,6’ -diisopropoxy- 1,1’ -biphenyl)[2-(2’ -amino- 1,1’- biphenyl)]palladium(II) (Ruphos-Pd G2, 99 mg, 0.14 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was cooled, concentrated and purified by silica gel chromatography to afford the desired product. LCMS calculated for C₂₄H₂₈N₇O₂(M+H)⁺: m/z = 446.2; found 446.2.

Step 2. 1, 3, 6-Trimethyl-4-( 3-(l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5- yl)piperazin-2-one

A solution of 4-(l-(4-methoxybenzyl)-3-(l -methyl-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-b ]pyridin-5-yl)-l,6-dimethylpiperazin-2-one (20 mg, 0.043 mmol) in THF was treated with LDA (2.0 M THF solution, 46 mL, 0.092 mmol) at -78 °C. The resulting solution was stirred at this temperature for 20 min before methyl iodide (8 mΐ, 0.092 mmol) was added. The reaction was slowly warmed up to r.t. and stirred for additional 20 min. After completion, the reaction was treated with sat. aq. NH4CI, and extracted with EtOAc. The organic phases were combined, washed with water and sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was cooled, concentrated and purified by prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for Ci7H22N₇0(M+H)⁺: m/z = 340.2; found 340.2. Example 16. 3-Isopropyl-l-methyl-4-(3-(l-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-1H- pyrazolo [4,3-b] pyridin-5-yl)piperazin-2-one

Step 1. 5-Chloro-l-(4-methoxybenzyl)-1H-pyrazolo[ 4, 3-b ] pyridine

A solution of 5-chloro-1H-pyrazolo[4,3-b ]pyridine (7.1 g, 46.5 mmol) in DMF (60 mL) was treated with l-(chloromethyl)-4-methoxybenzene (7.60 ml, 55.8 mmol) and K2CO3 (7.71 g, 55.8 mmol). The reaction mixture was stirred at 90°C for 1 h. The reaction mixture was cooled to r.t., diluted with water and extracted with EtOAc 3 times. The combined organic phases were washed with sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C₁₄H₁₃CIN₃O (M+H)⁺: m/z = 274.1; found 274.0.

Step 2. 3-Isopropyl-4-( 1 -(4-methoxybenzyl)-1H-pyrazolo [ 4, 3-b ]pyridin-5-yl)-l- methylpiperazin-2-one

A solution of 5-chloro-l-(4-methoxybenzyl)-1H-pyrazolo[4,3-b ]pyridine (387 mg, 1.42 mmol) in 1,4-dioxane (5 mL) was treated with 3-isopropyl-l-methylpiperazin-2-one (265 mg, 1.7 mmol), CS2CO3 (1.15 g, 3.5 mmol), and chloro(2-dicyclohexylphosphino-2’,6’- diisopropoxy- 1, 1'-biphenyl)[2-(2’ -amino- 1, 1'-biphenyl)]palladium(II) (Ruphos-Pd G2, 99 mg, 0.14 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was cooled, concentrated and purified by silica gel chromatography to afford the desired product. LCMS calculated for C₂₂H₂₈N₅O₂(M+H)⁺: m/z = 394.2; found 394.2.

Step 3. 4-(3-Iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-isopropyl-1- methylpiperazin-2-one

3-Isopropyl-4-(l-(4-methoxybenzyl)-1H-pyrazolo[4,3-b ]pyridin-5-yl)-1- methylpiperazin-2-one (400 mg, 1.01 mmol) was dissolved in 1 mL TFA and heated at 100 °C for 1 h. The reaction mixture was then concentrated and treated with sat. aq. NaHCO₃.

The mixture was extracted with DCM 3 times, the combined organic phases were washed with sat. aq. NaCl and dried over Na₂SO ₄. The solvent was concentrated and DMF (3 mL) was added to the residue followed by N-iodosuccinimide (226 mg, 1.01 mmol). The mixture was heated to 80 °C for 1 h before K2CO3 (168 mg, 1.2 mmol) and l-(chloromethyl)-4- methoxybenzene (0.16 ml, 1.21 mmol) were added. The reaction was heated at the same temperature for 30 min. The reaction was then cooled to r.t. and diluted with water. The mixture was extracted with EtOAc 3 times, the combined organic phases were washed with sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C22H27IN5O2 (M+H)⁺: m/z = 520.1; found 520.0.

Step 4. 3-Isopropyl-1-methyl-4-(3-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3- b]pyridin-5-yl)piperazin-2-one

A solution of 4-(3-Iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b ]pyridin-5-yl)-3- isopropyl-l-methylpiperazin-2-one (20 mg, 0.038 mmol) in 1,4-dioxane (0.5 mL) and water (0.1 mL) was treated with 3-((4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-1H-pyrazol-l- yl)methyl)pyridine (11 mg, 0.04 mmol), potassium phosphate (19 mg, 0.08 mmol), and [dichloro[1, 1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (4 mg, 0.005 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 2 h. The reaction mixture was then concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. This reaction mixture was concentrated and purified by prep-LCMS (XB ridge Cl 8 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for C₂₃H₂₇N₈O(M+H)⁺: m/z = 431.2; found 431.2.

Example 17. 3-Isopropyl-l-methyl-4-(3-(l-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H- pyrazolo [4,3 -b] pyridin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 16, using 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-l- yl)ethyl)morpholine instead of 3-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- pyrazol-l-yl)methyl)pyridine in step 4. LC-MS calculated for C23H33N8O2 (M+H)⁺ : m/z = 453.3; found 453.3.

Example 18. 4-(3-(3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-isopropyl-1-methylpiperazin-2-one

This compound was prepared according to the procedure described in Example 16, using 1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-methylpiperazine instead of 3 -((4-(4,4, 5 , 5 -tetramethyl -1,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazol- 1 - yl)methyl)pyridine in step 4. The product was isolated as the TFA salt. LC-MS calculated for C25H33N7OF (M+H)⁺ : m/z = 466.3; found 466.3.

Example 19. 3-Isopropyl-l-methyl-4-(3-(thieno[3,2-c]pyridin-2-yl)-lH-pyrazolo[4,3- b]pyridin-5-yl)piperazin-2-one

This compound was prepared according to the procedure described in Example 16, using 2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)thieno[3,2-c]pyridine instead of 3-((4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-1H-pyrazol-l-yl)methyl)pyridine in step 4. The product was isolated as the TFA salt. LC-MS calculated for C21H23N6OS (M+H)⁺ : m/z = 407.2; found 407.2.

Example 20. 3-Isopropyl-l-methyl-4-(3-(l-methyl-1H-l,2,3-triazol-4-yl)-1H- pyrazolo [4,3 -b] pyridin-5-yl)piperazin-2-one

Step 1. 3-Isopropyl-4-(l-(4-methoxybenzyl)-3-((trimethylsilyl)ethynyl)-1H-pyrazolo[4,3- b]pyridin-5-yl)-l-methylpiperazin-2-one

A solution of 4-(3-Iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-3- isopropyl-l-methylpiperazin-2-one (Example 16, step 3; 40 mg, 0.076 mmol) in 1,4-dioxane (1 mL) and water (0.1 mL) was treated with trimethyl((4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)ethynyl)silane (18 mg, 0.08 mmol), potassium phosphate (40 mg, 0.16 mmol), and [dichloro[1, 1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (8 mg, 0.01 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 80°C for 2 h. The reaction mixture was concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C27H36N5O2S1 (M+H)⁺: m/z = 490.3; found 490.3.

Step 2. 3-Isopropyl-l-methyl-4-( 3-( l -methyl- 1H-l, 2, 3-triazol-4-yl)-1H-pyrazolo[ 4, 3- b]pyridin-5-yl)piperazin-2-one

A solution of 3-isopropyl-4-(l-(4-methoxybenzyl)-3-((trimethylsilyl)ethynyl)-1H- pyrazolo[4,3-b]pyridin-5-yl)-l-methylpiperazin-2-one (30 mg, 0.06 mmol) in water (1 mL) was treated with iodomethane (0.007 mL, 0.12 mmol), sodium azide (5.2 mg, 0.08 mmol), copper(I) iodide (2 mg, 0.01) and L-(+)-ascorbic acid sodium salt (2 mg, 0.01 mmol). The reaction was heated at 75 °C for 10 h. The reaction mixture was extracted with EtOAc, which was then dried over Na₂SO ₄. The solvent was concentrated and the residue was dissolved in 0.5 mL of TFA and heated at 100 °C for 1 h. The reaction mixture was cooled, concentrated and purified by prep-LCMS (XB ridge Cl 8 column, eluting with a gradient of

acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for C₁₇H₂₃N₈O(M+H)⁺: m/z = 355.2; found 355.2.

Example 21. 4-(6-Chloro-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- l,3-dimethylpiperazin-2-one

Step 1. 6-Bromo-5-chloro-2-methylpyridin-3-amine

NBS (6.51 g, 36.6 mmol) was added to a solution of 5-chloro-2-methylpyridin-3- amine (4.97 g, 34.9 mmol) in DMF (349 ml). After stirring at r.t. for 30 min, water was added and precipitated product was collected by filtration and dried overnight in the air. The crude product was used in the next step without further purification. LCMS calculated for

C₆H7N₂BrCl(M+H)⁺: m/z = 221.0; found 221.0.

Step 2. N-(6-Bromo-5-chloro-2-methylpyridin-3-yl)acetamide

A solution of 6-bromo-5-chloro-2-methylpyridin-3-amine (7.0 g, 31.6 mmol) in acetic acid (79 mL) was treated with acetic anhydride (3.73 ml, 39.5 mmol). The reaction was stirred at 50 °C for lh, water was then added and the precipitated product was collected by filtration. It was used in the next step without further purification. LCMS calculated for C₈H₉N₂BrC10(M+H)⁺: m/z = 263.0; found 263.0.

Step 3. l-(5-Bromo-6-chloro-1H-pyrazolo[4,3-b]pyridin-l-yl)ethan-l-one

A suspension of N-(6-bromo-5-chloro-2-methylpyridin-3-yl)acetamide (7.2 g, 27.3 mmol) in toluene (137 ml) was treated with acetic anhydride (7.73 ml, 82 mmol), potassium acetate (3.22 g, 32.8 mmol) and isopentyl nitrite (5.87 ml, 43.7 mmol). The reaction mixture was heated at 100 °C for 2 h and then cooled and diluted with EtOAc. The mixture was washed with sat. aq. NaHCO₃ and brine, and dried over Na₂SO ₄. The solvent was removed under vacuum to afford the brown solid as the crude product which was used directly in next step without purification. LCMS calculated for C₈H₆N₃BrClO(M+H)⁺: m/z = 274.0; found 274.0.

Step 4. 5-Bromo-6-chloro-1H-pyrazolo[4,3-b]pyridine

A solution of 1 -(5-bromo-6-chloro- 1H-pyrazolo[4,3-/i]pyridin- l -yl)ethan- 1 -one (7g, 25.5 mmol) in THF (31.9 ml) and methanol (31.9 ml) was treated with 1M solution of sodium hydroxide (38.3 ml, 38.3 mmol). The mixture was stirred at 50 °C for lh. After completion, most of the solvent was evaporated and IN HC1 (40 mL) was added. The mixture was treated with 200 mL of water and a brown solid slowly formed during stirring of the reaction. The crude product was collected by filtration and used in the next step without further purification. LCMS calculated for C₆H₄N₃BrCl(M+H)⁺: m/z = 232.0; found 232.0.

Step 5. 5-Bromo-6-chloro-3-iodo-l-( 4-methoxybenzyl)-1H-pyrazolo[ 4, 3-b ] pyridine

A solution of 5-bromo-6-chloro-1H-pyrazolo[4,3-b ]pyridine (4g, 17.21 mmol) in DMF (20 mL) was treated with A-iodosuccinimide (3.87 g, 17.21 mmol). The mixture was heated to 80 °C for 1 h and then K2CO3 (2.85 g, 20.65 mmol) and l-(chloromethyl)-4- methoxybenzene (2.69 ml, 20.65 mmol) were added. The reaction was heated at the same temperature for 30 min. After completion, the reaction was cooled to r.t. and diluted with water. The mixture was extracted with EtOAc 3 times, the combined organic phases were washed with sat. aq. NaCl, dried with Na₂SO ₄, filtered and concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C ₁₄H ₁₁BrClIN₃O (M+H)⁺: m/z = 477.8; found 477.9. Step 6. 5-Bromo-6-chloro-l-(4-methoxybenzyl)-3-( 1 -methyl- 1H-pyrazol-4-yl)- 1H- pyrazolo[ 4, 3-b ] pyridine

A solution of 5-bromo-6-chloro-3-Iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3- b]pyridine (3 g, 6.27 mmol) in 1,4-dioxane (50 mL) and water (5 mL) was treated with 1- methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.304 g, 6.27 mmol), potassium phosphate (2.66 g, 12.54 mmol), and dichloro[l,T- bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.512 g, 0.627 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 80°C for 8 h. The reaction mixture was cooled to r.t., diluted with EtOAc, washed sequentially with water and sat. aq. NaCl, and dried over Na2S04. The organic phases were filtered and concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C₁₈H ₁₆ClBrN₅O (M+H)⁺: m/z = 432.1; found 432.1.

Step 7. 4-(6-Chloro-l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ]pyridin-5-yl)-l, 3-dimethylpiperazin-2-one

A solution of 5-bromo-6-chloro-l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)- 1H-pyrazolo[4,3-b ]pyridine (240 mg, 0.56 mmol) in 1,4-dioxane (5 mL) was treated with l,3-dimethylpiperazin-2-one (70 mg, 0.57 mmol), CS2CO3 (357 mg, 1.1 mmol), and chloro(2- dicy clohexylphosphino-2’ ,6’ -dii sopropoxy- 1,1’ -biphenyl) [2-(2’ -amino- 1,1’- biphenyl)]palladium(II) (Ruphos-Pd G2, 39 mg, 56.5 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 8 h. The reaction mixture was concentrated to dryness. The residue was purified by silica gel chromatography to afford the desired product. LC-MS calculated for C24H27CIN7O2 (M+H)⁺: m/z = 480.2; found 480.2.

Step 8. 4-( 6-Chloro-3-( l -methyl- 1H-pyrazol-4-yl)-1H-pyrazolo[ 4, 3-b ]pyridin-5-yl)-l, 3- dimethylpiperazin-2-one

4-(6-Chloro- 1 -(4-methoxybenzyl)-3 -(1 -methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b]pyridin-5-yl)-l,3-dimethylpiperazin-2-one (10 mg, 0.02 mmol) was dissolved in 0.5 mL of TFA. The mixture was heated at 100°C for 1 h and then concentrated and purified by prep- LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LC-MS calculated for C16H19CIN7O (M+H)⁺: m/z = 360.1; found 360.2.

Example 22. l,3-Dimethyl-4-(6-methyl-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3- b ] pyr idin-5-yl)piperazin-2-one

A solution of 4-(6-chloro-l-(4-methoxybenzyl)-3-(l -methyl- 1H-pyrazol -4-yl)-1H- pyrazolo[4,3-b ]pyridin-5-yl)-l,3-dimethylpiperazin-2-one (Example 21, step 7; 18 mg, 0.038 mmol) in 1,4-dioxane (0.5 mL) and water (0.1 mL) was treated with 2,4,6-trimethyl- 1,3,5,2,4,6-trioxatriborinane (9.4 mg, 0.075 mmol), potassium phosphate (19 mg, 0.08 mmol), and chloro(2-dicyclohexylphosphino-2^,,4^,,6^,-triisopropyl-l, l ^,-biphenyl)[2-(2’- amino- 1, 1'-biphenyl)]palladium(II) (4 mg, 0.005 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 2 h. The reaction mixture was concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was cooled, concentrated and purified by prep-LCMS (XBridge C₁₈ column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for C₁₇H₂₂N₇0(M+H)⁺: m/z = 340.2; found 340.2. Example 23. 5-(2,4-Dimethyl-3-oxopiperazin-l-yl)-3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo [4,3-b] pyridine-6-carbonitrile

A solution of 4-(6-chloro-l-(4-methoxybenzyl)-3-(l-methyl-1H-pyrazol-4-yl)-1H- pyrazolo[4,3-b ]pyridin-5-yl)-l,3-dimethylpiperazin-2-one (Example 21, step 7; 18 mg, 0.038 mmol) in 1,4-dioxane (0.5 mL) and water (0.2 mL) was treated with potassium

hexacyanoferrate(II) trihydrate (32 mg, 0.075 mmol), potassium acetate (3.68 mg, 0.038 mmol), and [(2-di-tert-butylphosphino-2’ ,4’ ,6’ -trii sopropyl- 1 , 1’ -biphenyl)-2-(2’ -amino- 1,1’- biphenyl)] palladium(II) methanesulfonate (4 mg, 0.005 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 2 h. The reaction mixture was then concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was cooled, concentrated and purified by prep- LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for C_I7H₁₉N₈O(M+H)⁺: m/z = 351.1; found 351.2.

Example 24. 4-(6-Methoxy-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5- yl)-l,3-dimethylpiperazin-2-one

A solution of 4-(6-chloro-l-(4-methoxybenzyl)-3-(l -methyl-1H-pyrazol -4-yl)-1H- pyrazolo[4,3-b ]pyridin-5-yl)-l,3-dimethylpiperazin-2-one (Example 21, step 7; 18 mg, 0.038 mmol) in toluene (0.5 mL) and MeOH (0.1 mL) was treated with CS2CO3 (24.44 mg, 0.075 mmol), and [(2-di-tert-butylphosphino-2’ ,4’ ,6’ -trii sopropyl- 1 , 1’ -biphenyl)-2-(2’ -amino- 1,1’- biphenyl)] palladium(II) methanesulfonate (4 mg, 0.005 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 2 h. The reaction mixture was then concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was concentrated and purified by prep-LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for CI7H22N₇02(M+H)⁺: m/z = 356.2; found 356.2.

Example 25. 4-(6-(Furan-3-yl)-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin- 5-yl)- 1 ,3-dimethylpiperazin-2-one

A solution of 4-(6-chloro-l-(4-methoxybenzyl)-3-(l -methyl- 1H-pyrazol -4-yl)-1H- pyrazolo[4,3-b ]pyridin-5-yl)-l,3-dimethylpiperazin-2-one (Example 21, step 7; 18 mg, 0.038 mmol) in 1,4-dioxane (0.5 mL) and water (0.1 mL) was treated with 2-(furan-3-yl)-4, 4,5,5- tetramethyl-l,3,2-dioxaborolane (8 mg, 0.04 mmol), potassium phosphate (19 mg, 0.08 mmol), and chloro(2-dicyclohexylphosphino-2^,,4^,,6^,-triisopropyl-l, l ^,-biphenyl)[2-(2’- amino-1, 1'-biphenyl)]palladium(II) (4 mg, 0.005 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 100°C for 2 h. The reaction mixture was then concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was concentrated and purified by prep-LCMS (XB ridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for

C2OH22N70₂(M+H)⁺: m/z = 392.2; found 392.2. Example 26. 4-(6-Benzyl-3-(l-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)- l,3-dimethylpiperazin-2-one

A solution of 4-(6-chloro-l-(4-methoxybenzyl)-3-(l -methyl- 1H-pyrazol-4-yl)- 1H- pyrazolo[4,3-b ]pyridin-5-yl)-l,3-dimethylpiperazin-2-one (Example 21, step 7; 18 mg, 0.038 mmol) in THF (1 mL) was treated with benzylzinc(II) bromide (0.5M THF solution, 0.14 mL, 0.07 mmol), Pd(OAc)2 (1.4 mg, 0.005 mmol) and 2-dicyclohexylphosphino-2’,6’- dimethoxybiphenyl (4 mg, 0.01 mmol). The reaction was degassed (by evacuation and backfilling with nitrogen) and stirred at 80°C for 8 h. The reaction mixture was then concentrated to dryness. The residue was dissolved in 0.5 mL of TFA and heated at 100°C for 1 h. The reaction mixture was concentrated and purified by prep-LCMS (XB ridge Cl 8 column, eluting with a gradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min). The product was isolated as the TFA salt. LCMS calculated for C23H26N70(M+H)⁺: m/z = 416.2; found 416.2.

Example A

FGFR Enzymatic Assay

The inhibitor potency of the exemplified compounds was measured in an enzyme assay that measures peptide phosphorylation using FRET measurements to detect product formation. Inhibitors were serially diluted in DMSO and a volume of 0.5 mL was transferred to the wells of a 384-well plate. For FGFR3, a 10 mL volume of FGFR3 enzyme (Millipore) diluted in assay buffer (50 mM HEPES, 10 mM MgCk, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated for a time between 5-10 minutes and up to 4 hours. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate. The assay was initiated by the addition of a 10 mL solution containing biotinylated EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP (final concentrations of 500 nM and 140 pM respectively) in assay buffer to the wells. The plate was incubated at 25 °C for 1 hr. The reactions were ended with the addition of 10 mL/well of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 30 mM EDTA with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin). The plate was allowed to equilibrate for ~1 hr before scanning the wells on a PheraStar plate reader (BMG Labtech).

GraphPad prism3 was used to analyze the data. The IC₅₀ values were derived by fitting the data to the equation for a sigmoidal dose-response with a variable slope.

Y=Bottom + (Top-Bottom)/(l+10^˄((Log IC₅₀-X)*HillSlope)) where X is the logarithm of concentration and Y is the response. Compounds having an IC₅₀ of 1 mM or less are considered active.

Table 1 provides IC₅₀ data for compounds of the invention assayed in the FGFR Enzymatic Assay after dilution in assay buffer, added to the plate and pre-incubated for 4 hours. The symbol:“+” indicates an IC₅₀ less than 10 nM;“++” indicates an IC₅₀ greater than or equal to 10 nM but less than 30 nM;“+++” indicates an IC₅₀ greater than or equal to 30 nM but less than 200 nM; and“++++” indicates an IC₅₀ greater than or equal to 200 nM. Table 1

Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

What is claimed is:

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

Cy¹ is selected from:

(i) C6-10 aryl,

S(0)NR^clR^dl, S(0)₂R^bl, and S(0)₂NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6- ₁₀ aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R²¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6- ₁₀ aryl -C 1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, OR^a4, SR^a4, C(0)R^b4, C(0)NR^c4R^d4, C(0)0R^a4, NR^c4R^d4, NR^c4C(0)R^M, NR^c4C(0)0R^a4, NR^c4S(0)R^M, NR^c4S(0)₂R^M, NR^c4S(0)₂NR^c4R^d4, S(0)R^b4, S(0)NR^c4R^d4, S(0)₂R^M, and S(0)₂NR^c4R^d4; wherein said C_1-6 alkyl, C₂-6 alkenyl, C₂-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

3 or 4 substituents independently selected from R²²;

each R^g is independently selected from OH, NO2, CN, halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C₃-₆ cycloalkyl, C₃-₆ cycloalkyl-Ci-2 alkylene, Ci-6 alkoxy, C_1-6 haloalkoxy, C1-3 alkoxy-C_1-3 alkyl, C1-3 alkoxy-C_1-3 alkoxy, HO-C1-3 alkoxy, HO-C1-3 alkyl, cyano-C 1-3 alkyl, H2N-C1-3 alkyl, amino, C_1-6 alkylamino, di(C_1-6 alkyl)amino, thio, C_1-6 alkylthio, C_1-6 alkylsulf yl, C_1-6 alkylsulfonyl, carbamyl, C_1-6 alkylcarbamyl, di(C_1-6 alkyl)carbamyl, carboxy, C_1-6 alkyl carbonyl, C_1-6 alkoxycarbonyl, C_1-6 alkylcarbonylamino, C_1-6 alkylsulfonylamino, aminosulfonyl, C_1-6 alkylaminosulfonyl, di(C_1-6 alkyl)aminosulfonyl, aminosulfonylamino, C_1-6 alkylaminosulfonylamino, di(C_1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C_1-6 alkylaminocarbonylamino, and di(C_1-6 alkyl)aminocarbonylamino.

2. The compound of claim 1, wherein Cy¹ is selected from monocyclic C6-10 aryl and monocyclic 5-6 membered heteroaryl; wherein each monocyclic 5-6 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized;

wherein a ring-forming carbon atom of the monocyclic 5-6 membered heteroaryl is optionally substituted by oxo to form a carbonyl group; and wherein the monocyclic C6-10 aryl and monocyclic 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

3. The compound of claim 1, wherein Cy¹ is selected from phenyl and monocyclic 5-6 membered heteroaryl having at least one ring-forming carbon atom and 1, 2, 3 or 4 ring forming nitrogen atoms; wherein the phenyl and monocyclic 5-6 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

4. The compound of claim 1, wherein Cy¹ is selected from thienopyridinyl, pyrazolyl, triazolyl and phenyl; wherein thienopyridinyl, pyrazolyl, triazolyl and phenyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰.

5. The compound of claim 1, wherein Cy¹ is selected from l-methyl-lH-pyrazol-4-yl, 1- methyl-lH-l,2,3-triazol-4-yl, l-(pyridin-3-ylmethyl)-lH-pyrazol-4-yl, l-(2- morpholinoethyl)-lH-pyrazol-4-yl, 3-fluoro-4-(4-methylpiperazin-l-yl)phenyl, and thieno[3,2-c]pyridin-2-yl.

6. The compound of any one of claims 1-4, wherein each R¹⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 memberedheterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl- C_1-3 alkylene, halo, D, CN, NO2, OR^al, SR^al, C(0)R^bl, C(0)NR^clR^dl, C(0)0R^al, 0C(0)R^bl, 0C(0)NR^clR^dl, and NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1,

2, 3, or 4 substituents independently selected from R¹¹.

7. The compound of any one of claims 1-4, wherein each R¹⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, halo, D, CN, OR^al, C(0)NR^clR^dl and R^clR^dl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

8. The compound of any one of claims 1-4, wherein each R¹⁰ is independently selected from C_1-6 alkyl, 4-10 membered heterocycloalkyl, and halo; wherein said C_1-6 alkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹.

9. The compound of any one of claims 1-4, wherein each R¹⁰ is independently selected from methyl, 4-methylpiperazin-l-yl, 2-morpholinoethyl, pyri din-3 -ylmethyl and fluoro.

10. The compound of any one of claims 1-4, wherein each R¹⁰ is methyl.

11. The compound of any one of claims 1-8, wherein each R¹¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl- C1-3 alkylene, halo, D, CN, OR^a3, SR^a3, C(0)R^b3, C(0)NR^c3R^d3, C(0)OR^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹².

12. The compound of any one of claims 1-8, wherein each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a3, SR^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹².

13. The compound of any one of claims 1-8, wherein each R¹¹ is independently selected from 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl.

14. The compound of any one of claims 1-8, wherein each R¹¹ is independently selected from 2-morpholino and pyridin-3-yl.

15. The compound of any one of claims 1-14, wherein Cy^A is 4-12 membered

heterocycloalkyl; wherein the 4-12 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of 4-12 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 4-12 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

16. The compound of any one of claims 1-14, wherein Cy^A is 6 membered

heterocycloalkyl; wherein the 6 membered heterocycloalkyl has at least one ring-forming carbon atom and 1 or 2 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of 6 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 6 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

17. The compound of any one of claims 1-14, wherein Cy^A is 6-membered

heterocycloalkyl selected from piperazinyl, piperidinyl, 5,6-dihydroimidazo[l,5-a]pyrazin- 7(8H)-yl and 6,7-dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl; wherein a ring-forming carbon atom of the 6-membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the 6 membered heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²⁰.

18. The compound of any one of claims 1-14, wherein Cy^A is 4-methyl-3-oxopiperazin-l- yl optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰.

19. The compound of any one of claims 1-14, wherein Cy^A is 4-12 membered

heterocycloalkyl, optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰; wherein the 4-12 membered heterocycloalkyl has at least one ring -forming carbon atom and 1, 2 or 3 ring-forming heteroatoms independently selected from N, O, and S;

wherein at least one of the ring-forming heteroatoms is N and wherein the 4-12 membered heterocycloalkyl is attached to the pyrazolopyridine core structure through a ring forming nitrogen atom.

20. The compound of any one of claims 1-14, wherein Cy^A is 4-12 membered

heterocycloalkyl, optionally substituted with 1, 2, or 3 substituents independently selected from R²⁰; wherein a ring-forming carbon atom of the 4-12 membered heterocycloalkyl is substituted by oxo to form a carbonyl group.

21. The compound of any one of claims 1-14, wherein Cy^A is selected from 3- hydroxypiperidin-l-yl, 6,7-dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl, l-(trifluoromethyl)- 5,6-dihydroimidazo[l,5-a]pyrazin-7(8H)-yl, 3-methyl-2-oxo-3,8-diazabicyclo[3.2.1]octan-8- yl, 2-isopropyl-4-methyl-3-oxopiperazin-l-yl, 2-ethyl-4-methyl-3-oxopiperazin-l-yl, 2,2- diethyl-4-methyl-3-oxopiperazin-l-yl, 2-benzyl-4-methyl-3-oxopiperazin-l-yl, 2- (cyclopropylmethyl)-4-methyl-3-oxopiperazin-l-yl, 4-methyl-3-oxo-2-(tetrahydro-2H-pyran- 4-yl)piperazin-l-yl, 4-methyl-3-oxo-2-(pyridin-4-ylmethyl)piperazin-l-yl, 4-methyl-3-oxo-2- (l-phenylethyl)piperazin-l-yl, 2-cyclopropyl-4-methyl-3-oxopiperazin-l-yl, 4-cyclopropyl-2- methyl-3-oxopiperazin-l-yl, and 2,4,5-trimethyl-3-oxopiperazin-l-yl.

22. The compound of any one of claims 1-20, wherein each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, halo, D, CN, OR^a2, C(0)NR^c2R^d2 and NR^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹; or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring, or a fused phenyl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6- membered heteroaryl ring, and fused phenyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹.

23. The compound of any one of claims 1-20, wherein each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, and OR^a2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

24. The compound of any one of claims 1-20, wherein two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6- membered heteroaryl ring, or a fused phenyl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6-membered heteroaryl ring, and fused phenyl ring are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹.

25. The compound of any one of claims 1-20, wherein each R²⁰ is independently selected from OH, methyl, ethyl, isopropyl, cyclopropyl, and tetrahydropyran, each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

26. The compound of any one of claims 1-20, wherein two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused bicycle such that Cy^A is selected from 5,6-dihydroimidazo[l,5-a]pyrazin-7(8H)-yl and 6,7- dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl; each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹.

27. The compound of any one of claims 1-26, wherein each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a4 and NR^c4R^d4; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

28. The compound of any one of claims 1-26, wherein each R²¹ is independently selected from C_1-6 haloalkyl, C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl.

29. The compound of any one of claims 1-26, wherein each R²¹ is independently selected from trifluorom ethyl, phenyl, pyridine and cyclopropyl.

30. The compound of any one of claims 1-22, wherein each R^a2, R^c2 and R^d2, is independently selected from H and C_1-6 alkyl.

31. The compound of any one of claims 1-22, wherein each R^a2 is H.

32. The compound of any one of claims 1-31, wherein R¹ is selected from H, D, and C_1-6 alkyl.

33. The compound of any one of claims 1-31, wherein R¹ is H.

34. The compound of any one of claims 1-33, wherein R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl -C 1-3 alkylene, halo, CN, OR^a7, SR^a7, C(0)R^b7, C(0)NR^c7R^d7, C(0)OR^a7, NR^c7R^d7, NR^c7C(0)R^b7, NR^c7C(0)0R^a7, NR^c7S(0)R^b7, NR^c7S(0)₂R^b7, NR^c7S(0)₂NR^c7R^d7, S(0)R^b7, S(0)NR^c7R^d7, S(0)2R^b7, and S(0)2NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1,

2, 3, or 4 substituents independently selected from R³⁰.

35. The compound of any one of claims 1-33, wherein R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered

heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C 1-3 alkylene, C6-10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl- C_1-3 alkylene, halo, CN, OR^a7, and NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 10 aryl -C 1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰.

36. The compound of any one of claims 1-33, wherein R² is selected from H, D, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-3 alkylene, halo, CN, OR^a7, and NR^c7R^d7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C6-10 aryl, 5-10 membered heteroaryl, and C6-10 aryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰.

37. The compound of any one of claims 1-33, wherein R² is selected from H, methyl, methoxy, chloride, nitrile, furanyl, and benzyl.

38. The compound of any one of claims 1-33, wherein R² is H.

39. The compound of any one of claims 1-33, wherein each R³⁰ is phenyl.

40. The compound of any one of claims 1-33, wherein each R^a7 is methyl.

41. The compound of any one of claims 1-4 and 6-40, herein the compound is a compound of Formula Ila:

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, 3, or 4.

42. The compound of any one of claims 1-4 and 6-40, wherein the compound is a compound of Formula lib:

lib

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2, or 3.

43. The compound of any one of claims 1-4 and 6-40, wherein the compound is a compound of Formula lie:

lie

or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2.

44. The compound of any one of claims 1, 4 and 6-40, wherein the compound is a compound of Formula lid:

lid

or a pharmaceutically acceptable salt thereof, wherein v is 1, 2, 3 or 4.

45. The compound of any one of claims 1-14 and 22-40, wherein the compound is a compound of Formula III:

or a pharmaceutically acceptable salt thereof, wherein q is 1, 2, or 3.

46. The compound of any one of claims 1-4, 6-14 and 22-40, wherein the compound is a compound of Formula IVa:

47. The compound of any one of claims 1-4, 6-14 and 22-40, wherein the compound is a compound of Formula IVb:

IVb

48. The compound of any one of claims 1-4, 6-14 and 22-40, wherein the compound is a compound of Formula IVc:

IVc

or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2 and wherein q is 1, 2, or 3.

49. The compound of any one of claims 1, 4, 6-14 and 22-40, wherein the compound is a compound of Formula IVd:

IVd

50. The compound of claim 1, wherein:

each R¹⁰ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C6- 1₀ aryl -C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, NO2, OR^al, SR^al, C(0)R^bl, C(0)NR^clR^dl, C(0)OR^al, OC(0)R^bl, OC(0)NR^clR^dl, and NR^clR^dl; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered

heterocycloalkyl-C_1-3 alkylene, C_6-10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl -C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹¹;

each R¹¹ is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 10 aryl-C_1-3 alkylene, 5-10 membered heteroaryl-C_1-3 alkylene, halo, D, CN, OR^a3, SR^a3, C(0)R^b3, C(0)NR^c3R^d3, C(0)OR^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, C_3-10 cycloalkyl-C_1-3 alkylene, 4-10 membered heterocycloalkyl-C_1-3 alkylene, C₆- 10 aryl-C_1-3 alkylene and 5-10 membered heteroaryl-C_1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²;

each R¹² is independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C3-6 cycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, 4-7 membered heterocycloalkyl, halo, D, CN, OR^a5, SR^a5, C(0)R^b5, C(0)NR^c5R^d5, C(0)0R^a5, NR^c5R^d5, and NR^c5C(0)R^b5; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C3-6 cycloalkyl, C6-10 aryl, 5- 10 membered heteroaryl and 4-7 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^g;

each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, halo, D, CN, OR^a2, C(0)NR^c2R^d2 and R^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

3 or 4 substituents independently selected from R²².

51. The compound of claim 1, wherein:

R¹ is selected from H, D, and C_1-6 alkyl;

R² is selected from H, D, C_1-6 alkyl, C_1-6 haloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-3 alkylene, halo, CN, and OR^a7; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C6-10 aryl, 5-10 membered heteroaryl, and C6-10 aryl -C 1-3 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R³⁰;

each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a3,

SR^a3, and NR^c3R^d3; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered

or two adjacent R²⁰ substituents on the Cy^A ring, taken together with the atoms to which they are attached, form a fused 5- or 6-membered heteroaryl ring; wherein each fused 5- or 6-membered heteroaryl ring has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of each fused 5- or 6-membered heteroaryl ring is optionally substituted by oxo to form a carbonyl group; and wherein the fused 5- or 6-membered heteroaryl ring, is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R²¹; and each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, C₆- 10 aryl, and 5-10 membered heteroaryl; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, C_6-10 aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²².

52. The compound of claim 1, wherein:

Cy¹ is selected from pyrazolyl, triazolyl and phenyl; wherein the pyrazolyl, triazolyl and phenyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^A is 4-12 membered heterocycloalkyl; wherein each 4-12 membered

R¹ is H;

each R¹¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, halo, D, CN, OR^a3 and NR^c3R^d3; wherein said C_1-6 alkyl, 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R¹²; each R²⁰ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, halo, D, CN, OR^a2, C(0)NR^c2R^d2 and NR^c2R^d2; wherein said C_1-6 alkyl, C_3-10 cycloalkyl and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²¹;

each R²¹ is independently selected from C_1-6 alkyl, C_1-6 haloalkyl, C_3-10 cycloalkyl, 4- 10 membered heterocycloalkyl, C_6-10 aryl, 5-10 membered heteroaryl, halo, D, CN, OR^a4 and NR^c4R^d4; wherein said C_1-6 alkyl, C_3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R²²;

each R³⁰ is independently selected from C_1-6 alkyl and phenyl;

53. The compound of claim 1, wherein:

Cy¹ is selected from pyrazolyl, triazolyl, phenyl and thienopyridinyl; wherein the pyrazolyl; triazolyl and phenyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R¹⁰;

Cy^A is 4-12 membered heterocycloalkyl; wherein each 4-12 membered

R¹ is H;

each R¹⁰ is independently selected from C_1-6 alkyl, and 4-10 membered

each R³⁰ is phenyl.

54. The compound of claim 1, wherein the compound is selected from:

l-(3-(l-Methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)piperidin-3-ol;

5-(6,7-Dihydropyrazolo[l,5-a]pyrimidin-4(5H)-yl)-3-(l -methyl- lH-pyrazol-4-yl)- 1H- pyrazolo[4,3-b]pyridine;

3-Methyl-8-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-3, 8- diazabicyclo[3.2.1 ]octan-2-one;

3, 3-Diethyl- l-methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5- yl)piperazin-2-one;

l-Methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-3- (tetrahydro-2H-pyran-4-yl)piperazin-2-one;

l-Methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-3- (pyridin-4-ylmethyl)piperazin-2-one;

l-Methyl-4-(3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-3-(l- phenylethyl)piperazin-2-one; 3-Cyclopropyl-l-methyl-4-(3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin- 5 -yl)piperazin-2-one;

3-Isopropyl-l -methyl -4-(3-(l -methyl-lH- 1,2, 3-triazol-4-yl)-lH-pyrazolo[4, 3- b]pyridin-5-yl)piperazin-2-one;

4-(6-Chloro-3-(l-methyl-lH-pyrazol-4-yl)-lH-pyrazolo[4,3-b]pyridin-5-yl)-l,3- dimethylpiperazin-2-one;

1, 3-Dimethyl -4-(6-methyl-3-(l -methyl- lH-pyrazol-4-yl)-lH-pyrazolo[4, 3-b]pyridin- 5 -yl)piperazin-2-one;

5-(2, 4-Dimethyl -3-oxopiperazin-l-yl)-3-(l -methyl- lH-pyrazol -4-yl)-lH- pyrazolo[4,3-b]pyridine-6-carbonitrile;

or a pharmaceutically acceptable salt thereof.

55. A pharmaceutical composition comprising a compound of any one of claims 1 to 54 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

56. A method of inhibiting an FGFR3 enzyme comprising contacting said enzyme with a compound of any one of claims 1 to 54 or a pharmaceutically acceptable salt thereof, or a composition of claim 55.

57. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 54 or a pharmaceutically acceptable salt thereof, or a composition of claim 55.

58. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 54 or a pharmaceutically acceptable salt thereof, or a composition of claim 55 in combination with another therapy or therapeutic agent.

59. The method of claim 57 or 58, wherein said cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin’s or non-Hodgkin’s lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

60. The method of claim 57 or 58 wherein said cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.